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In 1882, Mycobacterium tuberculosis (M. tuberculosis) was identified as the cause of 
tuberculosis (TB) by Robert Koch. TB is an infectious disease that is transmitted from 
person to person: humans are the reservoir of M. tuberculosis. Transmission occurs by 
inhalation of aerosolized droplets loaded with viable bacilli expelled into the air through 
coughing and sneezing, by individuals with pulmonary TB. TB primarily affects the lungs, 
and indeed, most TB patients have pulmonary TB; but TB may also affect the central 
nervous system and virtually any other organ system. In 1905, Koch was awarded with 
the Nobel Prize for his discovery of the tubercle bacillus, but only in 1943, the first anti-TB 
drug – streptomycin was discovered, for which Selman Waksman was awarded with the 
Nobel Prize in 1952. In affluent countries, TB incidence had already started to decline well 
before the advent of effective antimicrobial chemotherapy in the 1950s. Philip D’Arcy-Hart 
working with the Tuberculosis Unit of the British Medical Research Council conducted 
the first randomized controlled trial showing a survival advantage for individuals given 
streptomycin [1]. In this trial it was shown that mono-therapy with streptomycin resulted 
in the emergence of drug-resistant organisms that eventually resulted in recurrence of TB, 
and subsequent death with resistant organisms. 
There is no doubt that combined drug therapy for TB has saved millions of lives in the 
last decades, and TB incidence has slightly decreased in recent years [2, 3]. Still, some 
9 million cases of TB were detected in 2011 worldwide, especially in low and middle 
income countries [4]. Two factors have seriously jeopardized the TB problem. First, the 
emergence of multidrug resistant (MDR) TB in the early 1990ties in New York and San 
Francisco were the harbinger of a new epidemic of MDR-TB. In addition, TB patients co-
infected with Human Immunodeficiency Virus (HIV) constitute a serious threat to global 
health, as HIV co-infection tremendously increases susceptibility to develop TB.  Today, 
MDR-TB is alarming especially in Eastern European countries [5]. MDR-TB is defined by 
resistance to isoniazid and rifampicin, the two most effective anti-tuberculous first line 
drugs. Extensively drug-resistant tuberculosis (XDR) is defined as MDR-TB with additional 
resistance to a fluoroquinolone and injectable second-line therapy including capreomycin, 
kanamycin or amikacin [6]. Treatment of MDR-TB and XDR-TB is challenging; to date only 
treatments including rifampicin in combination with pyrazinamide have been shown to 
have sterilizing capacity when used in a short-course (i.e., six- months’ duration) regimen. 
By necessity, MDR-TB and XDR-TB required prolonged treatment; current WHO guidelines 
now recommend 20 months of treatment, with at least 6 months’ duration of injectables if 
in vitro susceptibility has been demonstrated. With increasing loss of susceptibility to the 
remaining agents, the chances of sputum conversion, and finally cure, diminish. Indeed, 
new effective anti-TB drugs are urgently needed. Recently, bedaquiline (TMC207) was 
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approved by food and drug administration (FDA) although, because of concerns about 
safety, a decision by European Medicines Agency (EMA) was postponed. Delamanid was 
recently approved by the EMA. Other new compounds currently being evaluated are PA-
824, SQ109, PNU-100480 and AZD5847 [7]. 
Unfortunately, development of these new anti-TB drugs carries certain unknown risks 
of failure, even in late stages of development; and definitely it takes considerable time– 
around 12 years – before they finally reach the market and even after introduction, 
several products may still show unanticipated toxicity if wider used, and may need to be 
withdrawn from the market like trovafloxacin and grepafloxacin because of hepatotoxicity 
and cardio toxicity respectively. Besides, the search for new drugs is expensive and the 
low and middle income countries that constitute 95% of TB cases around the world have 
limited resources to support such research [8].  In order to speed up novel treatments 
for MDR-TB, new uses of approved (for other indications) existing drugs that are already 
available in the market could have an important role in MDR-TB treatment [9,10].
One of these drugs is moxifloxacin, a new generation fluoroquinolone that showed 
activity against M. tuberculosis. Although moxifloxacin is not registered for this indication, 
this drug is recommended for MDR-TB treatment [11,12]. Another new fluoroquinolone is 
gatifloxacin [13].
One of the drugs available in the market that is a potential candidate drug for TB is co-
trimoxazole (SXT) because it is inexpensive, well tolerated and available worldwide but 
more importantly also in low and middle income countries [14]. SXT is a synergistic 
combination of trimethoprim (TMP) and sulfamethoxazole (SMX) in a ratio of 1:5. Both 
TMP and SMX are folic acid antagonist agents [15]. 
After oral administration, TMP is almost completely absorbed within 2-3 hours while 
the total absorption of SMX is 85-90%.  Both of SMX and TMP are distributed in tissues 
that may be affected by TB like lung and brain.  Following distribution, 60-80% of a total 
TMP appears in urine in an unchanged form and the rest are metabolites. Two of these 
metabolites are excreted in free and glucuronide forms, the latter, constitute 10-15% of 
total TMP concentration in the blood.  For SMX, 60-65% of a total SMX is metabolized as 
the N4 – acetyl derivative and 15% as N1 glucuronide and these metabolites constitute 70% 
of total SMX in urine and 20-35% in plasma. Because of the relative long half-lives of SXT 
components, this drug is given every 8-12 hours for labeled indications [16].
SXT is prescribed for treatment of different diseases including urinary tract and respiratory 
infections. In patients with HIV, SXT provides prophylactic and therapeutic activity 
against Pneumocystis jiroveci pneumonia (PCP) [17-21]. The drug is available as tablets, 
oral suspension and parenteral formulation which is very convenient to treat patients in 
different stages of illness. 
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In general, a number of pharmacokinetic (PK) in relation to pharmacodynamic (PD) 
parameters predict the efficacy of antimicrobial agents [22].  They include the ratio of 
area under the concentration-time curve (AUC) from 0 to 24 relative to the minimum 
inhibitory concentration (MIC) (AUC/MIC) and the duration of time a drug concentration 
remains above the MIC (t>MIC) [23]. Because PK/PD studies are relative new, an old drug 
like SXT lacks data compared to newer drugs because these PK/PD studies have not been 
performed yet. Only in vitro data regarding SXT against Bukholderia pseudomallei are 
available and these data show that AUC/MIC ratio should exceed 25 [24]. As SXT is used for 
long-term prophylaxis of PCP HIV infected patients, the emergence of resistance among a 
range of pathogens has unfortunately been observed [25,26].
Limited data are available on the use of SXT for TB. Drug susceptibility data are scare, 
mechanism of resistance is unknown, little is known about the PK of SXT in TB patients 
and PK/PD parameters of SXT against M. tuberculosis are also unknown. Therefore, it is 
a challenge to establish a suitable dose of this drug for TB, especially in case of MDR-TB.
OBJECTIVES
The general aim of this thesis is to explore the potential use of SXT for TB treatment by 
evaluating pharmacokinetic parameters in TB patients, drug susceptibility against M. 
tuberculosis (PD) and PK/PD parameters of this drug. 
OUTLINE
Chapter 1. In the first chapter we reviewed the in vitro, in vivo and clinical anti-tuberculosis 
(anti-TB) activity of six antimicrobial drugs (thioridazine, metronidazole, doxycycline, 
disulfiram, tigecycline and co-trimoxazole). These drugs are already available in the market 
and are not listed in WHO guidelines on MDR-TB treatment. These drugs may prove to be 
potential candidates for the treatment against M. tuberculosis or may serve as a lead for 
future drug development.
Chapter 2.  Based on drug susceptibility tests and lacking other active antimicrobial 
drugs, SXT has been administered to individual patients in our center.  Due to lack of the 
PK and PD parameters of this drug in MDR-TB patients, we retrospectively evaluated these 
parameters for SMX (the effective component of SXT against M. tuberculosis) along with 
its tolerability and safety. To further explore the PK in TB patients and compare it with 
other patients, a population PK model (POP-PK) would be developed to be useful for the 
assessment of potential altered PK parameters in MDR-TB patients. 
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Chapter 3.  To assess the susceptibility of M. tuberculosis isolates to SMX among different 
TB patients, we selected isolates from two groups of TB patients: (normal sensitive TB and 
HIV-co infected TB). Consequently, we compared the susceptibility of these isolates to 
SMX with that of MDR-TB patients from the retrospective study (chapter 2).  
Chapter 4. In order to measure the concentrations of SMX and its toxic metabolite in 
plasma or serum to find the relationship between the concentration of SMX and toxicity 
of its metabolites and efficacy of SMX, we developed a new analyzing method liquid 
chromatography mass spectrometry (LC-MS/MS).
Chapter 5. Using the developed LC-MS/MS method, we performed a prospective study to 
measure the PK and PD of SMX in normal sensitive TB patients. Furthermore, we calculated 
the values of ƒ AUC/MIC ratio and T>MIC to be as a reference to measure the efficacy of 
SMX part of SXT and subsequently to find the suitable dose in the treatment of TB. 
In Chapter 6 we developed and validated dried blood spot (DBS) as a method to collect 
the blood samples. DBS is necessarily needed to quantify the concentrations of SMX and 
its metabolites for therapeutic drug monitoring. 
The last section of the thesis, Chapter 7, includes summary, conclusion of important 
findings, general discussion, limitations of the research and their effect on the research 
results and future prospective. 
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ABSTRACT
Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging because of the high 
toxicity of second-line drugs and the longer treatment duration than for drug-susceptible 
TB patients. In order to speed up novel treatment for MDR-TB, we suggest considering 
expanding the indications of already available drugs. Six drugs with antimicrobial activity 
(phenothiazine, metronidazole, doxycycline, disulfiram, tigecycline and co-trimoxazole) 
are not listed in WHO guidelines on MDR-TB treatment but could be potential candidates 
for evaluation against M. tuberculosis. 
A systematic review was conducted to evaluate antituberculous (anti-TB) activity of these 
drugs against M. tuberculosis. We searched PubMed, Google scholar and Embase for 
English articles published up to December 31, 2012.
We reviewed in vitro, in vivo and clinical anti-TB activity of these drugs in addition to 
pharmacokinetics (PK) and side effects. Of the drugs effective against active replicating TB, 
co-trimoxazole seems the most promising one because of its consistent pharmacokinetic 
profile, easy penetration into tissue and safety profile. For the dormant state of TB, 
thioridazine may play a potential role as an adjuvant for treatment of MDR-TB. A strategy 
consisting of PK/PD studies, dose finding and phase III study is needed to explore these 
drugs for their role in MDR-TB treatment
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Multidrug-resistant (MDR) tuberculosis (TB) is defined as an infectious disease caused 
by Mycobacterium tuberculosis (M. tuberculosis) that is resistant to the two most powerful 
drugs currently known: isoniazid and rifampin [1-4]. Treatment of MDR-TB is complex, using 
toxic drugs that must be administered for a longer duration than for drug-susceptible TB 
patients, and with lower likelihood of treatment success [5].
The loss of rifampin in the treatment regimen of MDR-TB is particularly important because 
although many drugs have the potential to kill rapidly dividing metabolically active 
mycobacteria, few drugs are active when the population of M. tuberculosis has switched its 
genetic program to a quiescent, dormant phenotype. These persisters provide the major 
challenge for the immune system as well as for drug treatment to achieve sterility [6].
WHO estimates that 2.5% of all TB patients and 3% of all new cases are infected with MDR-
TB [7,8]; an estimated 650,000 prevalent cases of MDR-TB occurred globally in 2010 [9]. 
The proportions of new TB cases with MDR-TB at the country level in Eastern European 
countries range at an alarming level of 19.4-32.3% [10]. One recent report from Belarus 
even indicates that almost half of newly diagnosed treatment-naïve patients with TB 
actually have MDR-TB. Further, the fact that patients < 35 years of age showed twofold 
higher odds of MDR-TB than those aged ≥35 suggests that emergence of MDR-TB is 
rampant in Belarus [11].
Most of the drug resistance is caused by mutations in the genome of M. tuberculosis coding 
for drug targets, but there is also evidence for mutations resulting in upregulation of 
bacterial efflux pumps, potentially reducing susceptibility for several drug groups [12, 13]. 
An important feature of M. tuberculosis is that under stress conditions, including hypoxia 
and host factors like nitric oxide, the organism is able to change its genetic program by 
e.g. inducing a 48-gene regulon via the response regulator DosR; this leads to inhibited 
aerobic respiration, thereby suppressing M tuberculosis replication [14].
It is clear that new antituberculous drugs are urgently needed. Unfortunately, development 
of new drugs takes time, is difficult and expensive, and low- and middle-income 
countries that comprise 95% of TB cases around the world have limited resources for 
health expenditure as well as lack of support for research [15]. In order to speed up 
novel treatments for MDR-TB, in this paper we explore the possibility of expanding the 
indications of drugs already available on the market.
We performed a systematic review of the published literature to select and describe 
antimicrobial drugs that are not listed in WHO guidelines on MDR-TB but may have in 
vitro and/or in vivo or clinical antituberculous activity, and are already available on the 
market labelled for other diseases. Based on these data, in addition to pharmacokinetic 
Alsaad.indd   17 12-10-2016   11:53:32
Chapter 1 Potential antimicrobial agents for the treatment of MDR-TB
18 
parameters, administration route, safety and tolerance of the selected drugs, suggestions 
are made as to which drug is promising so that it can be further evaluated for MDR-TB 
treatment. 
SEARCH STRATEGY AND SELECTION CRITERIA:
To select antimicrobial drugs for our systematic review that have activity against M. 
tuberculosis, we used the following search strategy in Pubmed: antimicrobial drugs 
AND tuberculosis AND 2012. To assess the activity of the selected drugs, we performed 
a second search in the databases PubMed, Google scholar and Embase for published, 
original and relevant literature with search terms that included but weren’t restricted 
to the name of each drug combined with M. tuberculosis. Selection criteria were activity 
of the selected drug against M. tuberculosis in vitro, in vivo and/or clinical studies. In 
vitro studies that described susceptibility to the drug of interest were selected. In vivo 
also included animal studies infected with M. tuberculosis describing the log decline in 
colony-forming units CFU of M. tuberculosis per kilogram of body mass following drug 
administration. Clinical studies included clinical trials that described efficacy, sputum 
culture conversion and clinical outcome in MDR-TB patients. Further cross-references 
were obtained manually from bibliographies of identified and relevant papers and books. 
English-language publications covering all dates from the creation of each database up 
to December 31, 2012 were included. To evaluate relevant pharmacokinetic parameters, 
safety and tolerance of the drugs, studies in TB patients were selected. If the latter were 
not available, representative data of the drugs were presented. The results were divided 
per drug, using within each case the subheadings in vitro, in vivo and clinical data. A flow 
chart is presented in figure 1.
    
Alsaad.indd   18 12-10-2016   11:53:32
1Potential antimicrobial agents for the treatment of MDR-TB
19 
Chapter 1
FIGURE 1- Flow chart of the selection process of retrieved publications: (a) selection of antimicrobial drugs, (b) selection of publications 
RESULTS
Based on the first search strategy, 783 publications were retrieved. Screening of the titles 
and abstracts of these publications resulted in six antimicrobial drugs that are available on 
the market and not listed for tuberculosis in WHO guidelines. The selected antimicrobial 
drugs were phenothiazines (thioridazine and chlorpromazine), metronidazole, tetracyclines, 
disulfiram and co-trimoxazole (sulfamethoxazole-trimethoprim).
Our second search strategy resulted in 191 published articles. Based on screening of the 
titles 85 articles were selected, and 106 articles were excluded because of non-relevant 
titles. The abstracts of 85 articles were screened; 56 were excluded because the selection 
criteria weren’t met. Finally, 29 relevant articles in addition to 4 articles form Google 
scholar and 3 references from the books were included in the systematic review. The 
search in Embase did not result in additional articles compared to PubMed. The results 
for each drug are discussed in detail below. A summary of the results, based on in vitro, 
in vivo and clinical data is provided in Table 1. Mechanisms of actions of these drugs are 
described in Figure 2. Pros and cons of the selected drugs are summarised in Table 2. The 
clinically evaluated dose and the effect of the drugs against TB are summarised in Table 3.
Selection of antimicrobial drugs
‘’antimicrobial drugs AND tuberculosis AND 2012’’
Titles and abstracts screening                                  
‘’antimicrobial drugs AND tuberculosis AND 2012’’
Six antimicrobial drugs identified
Citations identified in Pubmed (n=783)
Assessment of activity of antimicrobial drugs 
in vitro OR in vivo OR clinical
Title and Abstract screening in vitro OR in vivo
OR clinical
Citation based on title (n=85)
Citations identified in Pubmed and Embase
(n=191)
Relevant articles (n=29)
Articles included in this review (n=36)
Title and Abstract screening
in vitro OR in vivo OR clinical
Excluded (n=106) because of non-relevant 
=citation (n=106)
Excluded because the selection criteria (n=56) 
Additional studies identified from Google 
scholar and books (n=7)
1a
1b
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FIGURE 2-The mechanisms of action of the selected drugs. PABA: p-aminobenzoic acid; DHPS: dihydropteroate synthase; DHF: 
dihydrofolate; DHFR: DHF reductase; THF: tetrahydrofolic acid; SMX: sulfamethoxazole; TMP: trimethoprim; β-CA: β-class carbonic 
anhydrase







CO2 hydration ( β-CA inhibition)
Disulfiram
Protein synthesis (30S inhibition)
Tetracyclines














Alsaad.indd   21 12-10-2016   11:53:33



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Alsaad.indd   22 12-10-2016   11:53:33
















































































































































































































































































































































































































































































































































Alsaad.indd   23 12-10-2016   11:53:33
Chapter 1 Potential antimicrobial agents for the treatment of MDR-TB
24 
PHENOTHIAZINES - THIORIZADINE
Phenothiazines such as thioridazine, chlorpromazine and promethazine belong to 
the group of anti-psychotic drugs [16]. The phenothiazine derivative thioridazine is a 
neuroleptic compound that has been used for over four decades [17]. Phenothiazines 
have the ability to inhibit the bacterial efflux pump which protects the bacterial cell 
against harmful substances to which the cell is exposed [16]. Thioridazine not only inhibits 
specific efflux pump systems but also the expression of genes that code for efflux pumps 
of M. tuberculosis [18].
In vitro studies
Phenothiazine family compounds, including chlorpromazine and thioridazine, are known 
to possess appreciable levels of antimicrobial activity against MTB organisms in vitro. 
The anti-MDR-TB activity was similar in thioridazine and chlorpromazine [19]. These 
compounds may be concentrated more than tenfold by macrophages that phagocytise TB 
tuberculosis bacilli [20]. It is likely that the concentration of either phenothiazine required 
to kill M. tuberculosis cells in vitro is achieved not only because the macrophage is able to 
concentrate phenothiazines but also to make these compounds available in an active form 
to the cytoplasmic structure of the macrophage that houses the entrapped phagocytised 
bacterium [19]. Thioridazine inhibits the growth of clinical isolates of M. tuberculosis that 
are resistant to streptomycin, rifampin, isoniazid, ethambutol and pyrazinamide (first-line 
anti-TB drugs) [21]. Minimum inhibitory concentration of thioridazine required for 50% 
inhibition of M. tuberculosis H37Rv clinical isolates is 2.5 mg/L [22]. Because thioridazine 
does not appear toxic to the macrophage in vitro, it could be used in the treatment of 
intracellular M. tuberculosis infections [19].
In vivo studies
Groups of five female BALB/C mice were infected intraperitoneally with106 colony-forming 
units (CFU) /mL of M. tuberculosis and treated with thioridazine in a dose range 0.05-0.5 
mg/day, which is equivalent to that used for psychosis in humans (1200 mg/day). There 
was a higher-than-5 log reduction in the number of CFU/kg derived from the lungs of 
infected mice compared to the control group within one month [23].
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When thioridazine is administered orally it is rapidly absorbed, with peak plasma 
concentrations occurring within 2-3 hours. Thioridazine is widely distributed in tissues like 
liver, blood and kidney [24, 25], yet it is distributed less favourably to the brain [26]. It is 
not useful for treatment of cavitary pulmonary M. tuberculosis because the concentration 
of thioridazine required for killing or inhibiting M. tuberculosis outside the macrophage 
exceeded the concentration that could be achieved in patients receiving standard 
dosages [19].
Thioridazine undergoes 5-sulfoxidation and N-demethylation by CYP1A2 and CYP3A4, 
while CYP2D6 catalyses mono-2- and di-2-sulfoxidation of thioridazine in the human 
liver. CYP2D6 and CYP3A4 catalyse thioridazine mono-2-sulfoxidation [27]. Thioridazine 
is almost entirely (99.85%) bound to serum proteins; its metabolites are bound to serum 
proteins to a lesser extent. This could be a problem because a small change in the 
binding capacity of proteins can alter the unbound concentration of thioridazine that 
has clinical activity. The unbound concentrations of thioridazine metabolites that include 
thioridazine side-chain sulfoxide and thioridazine side-chain sulfone are higher (2 and 9 
times respectively) than the unbound concentration of thioridazine [28].
Thioridazine can be used as adjuvant for regimens already containing several other drugs 
for treatment of MDRTB. It is administered in drug-resistant TB until the susceptibility of 
strains is known [20]. 
Of 17 XDR-TB patients, 14 were treated with thioridazine in combination with linezolid 
and/or moxifloxacin at a daily dose of only 25 mg for 2 weeks, after which the dose 
was increased by 25 mg weekly until it reached 200 mg/day. The combined therapy of 
thioridazine, moxifloxacin and linezolid cured 61% of patients, and 22% of patients who 
were still on follow-up showed beneficial response. Thioridazine was discontinued in two 
patients because of pancytopenia in one patient and allergic dermatitis in the other. In 
this study, the authors speculate that thioridazine could have contributed to an earlier 
bacteriological sputum conversion. No prolongation of the QT interval or other cardiac 
complication was observed in those patients who received thioridazine. Combined 
therapy including linezolid, moxifloxacin and thioridazine was associated with a relapse-
free cure in most cases [29]. The quality of life of the patients was improved shortly after 
the inclusion of thioridazine in their regimens; most of them benefited from less night 
sweating, increased appetite, weight gain and decreased levels of anxiety [29]. In another 
study, thioridazine cured 10 out of 12 patients; the other two patients responded too but 
they dropped out of the program [30].
The side effects of thioridazine, as for all phenothiazines, are dose-dependent and include 
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QTc prolongation, thereby increasing the risk of Torsade Pointes with subsequent risk of 
sudden death [31]. To avoid the risk of sudden death in patients whose QTc is significantly 
increased, patients should be screened by ECG before and during treatment with 
thioridazine [30]. Because chlorpromazine causes frequent and serious side effects when 
administered chronically, it is not a good candidate drug for treatment of MDR-TB [32].
METRONIDAZOLE
Metronidazole is currently licensed for the oral treatment of infections like protozoa 
(trichomoniasis, amaebiasis) and anaerobic bacteria [33]. This drug has only been evaluated 
to a limited extent for TB [33], showing good bactericidal action in anaerobic conditions 
against dormant TB bacilli, but has no effect on aerobic cultures of M. tuberculosis [33- 35].
Bactericidal activity of metronidazole depends on the formation of a redox intermediate 
metabolite from the reduction of the nitro group in metronidazole under anaerobic 
conditions. This metabolite oxidises DNA and causes extensive breakage of DNA strands 
and subsequent cell death, and also inhibits DNA-ase1, which has a function as a repair 
endonuclease in bacteria. Hence reduced metronidazole exerts a dual action by breaking 




Metronidazole showed no effect when added to bone marrow-derived macrophages 
infected with M. tuberculosis and did not decrease the bacterial load, although a high 
concentration of metronidazole was used [38]. Adding metronidazole to a regimen of 
rifampin, moxifloxacin and amikacin and/or capreomycin significantly improved killing of 
dormant (anaerobic and drug-tolerant) M. tuberculosis in an adipocyte model [39]. 
An in vitro study was conducted to determine the effect of metronidazole against tubercle 
bacilli incubated under aerobic conditions. Although a high concentration of metronidazole 
was used (512 µg/ml), it had no effect on aerobic cultures of M. tuberculosis. However, 
under anaerobic conditions, when 32 µg/ml of metronidazole was incubated with M. 
tuberculosis alone and in combination with either rifampicin or isoniazid, this caused a 
reduction of 69% and 95% in CFU/ml respectively. Again in this study, 8 days of anaerobic 
exposure of dormant bacilli to 8 µg/ml of metronidazole caused 2.7 log reductions in the 
number of CFU. Rifampicin enhanced the bactericidal activity of metronidazole when 
used in combination, leading to a 3.68 log unit decline in CFU/ml [34].
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Although metronidazole had no effect on the growth of M. tuberculosis in lungs of aerosol-
infected mice at a dose of 15 mg/kg, there was a relatively small but statistically significant 
reduction in bacterial counts during a chronic phase of disease. This chronic phase, in 
which no remarked changes in bacterial load can usually be detected, and established 
after the onset of acquired cellular immunity of mice as a result of the progressively 
growing M. tuberculosis, resulted in a proportion of bacilli shifting into a dormant state [38, 
40]. The possible explanation for the low activity of metronidazole is that M. tuberculosis 
is not in a state of anaerobic metabolism in which it is susceptible to metronidazole [38].
In another in vivo study using a granuloma model of M. tuberculosis dormancy (mouse 
hollow-fibre model), metronidazole (100 mg/kg) failed to show a beneficial effect against 
bacilli, although there was immunohistochemical and mutant survival-based evidence 
of tissue hypoxia. The possible explanations for this result could be a less-than-optimal 
concentration of metronidazole, poor penetration into granulomatous lesions or lack of 
hypoxic conditions to permit reductive activation of metronidazole [41].
Activity of metronidazole at 50 and 100 mg/kg in guinea-pigs infected with M. tuberculosis 
combined with standard regimens showed no significant activity, perhaps because of 
poor penetration of metronidazole into the necrotic core of the hypoxic granulomas or 
the concentrations of metronidazole effective against M. tuberculosis under completely 
anaerobic and microaerophilic conditions [42]. These results were comparable to the in 
vivo study, where treatment of BALB/c mice and C3HeB/FeJ mice that developed highly 
organized necrotic lesions following a TB infection called Kramnik model with 200 mg/
kg metronidazole for 7 to 8 weeks had no bactericidal activity against M. tuberculosis, 
although necrotic lesions in the Kramnik model showed evidence of hypoxia [43].
Clinical studies 
The oral bioavailability of metronidazole is almost complete (98.9%) [44] . Peak serum 
levels are reached within 1-3 hours [45]. Metronidazole is bound 10-20% to plasma 
proteins [45]. The half-life of metronidazole is about 8h [44]. Metronidazole is distributed 
in different tissues with various percentages of penetration, and it has good penetration 
into the cerebrospinal fluid (CSF) and central nervous system (CNS) [37]. It is metabolised 
in the liver, resulting in the formation of two oxidation products: the alcohol metabolite 
1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole, which has an antimicrobial activity of 
30-75% compared to metronidazole, and the acidic metabolite 2-methyl-5-nitroimidazole-
1-acetic acid, which has 5% activity of the metronidazole and is only detected in patients 
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with renal dysfunction [46, 47]. Metronidazole and its metabolites are mainly excreted in 
urine [48].
There are few clinical studies of metronidazole for TB. In a single-blinded study, metroni-
dazole (400 mg three times daily) or a placebo were administered for the first eight weeks 
in addition to the standard anti-TB regimen. Addition of metronidazole resulted in a sig-
nificant improvement in clinical response, with reduction of sputum quantity, enhanced 
radiographic improvement and improved sensitivity to anti-TB drugs compared to the 
placebo group. The results showed a 56% improvement in the sensitivity of tubercle ba-
cilli to anti-TB drugs on follow-up over 12 weeks in the metronidazole group, compared to 
38% in placebo group. This study confirmed that metronidazole has a beneficial adjuvant 
role in the treatment of TB [49].
In an ongoing clinical trial, metronidazole is used in MDR-TB patients at a dose of 500 mg 
three times daily in combination with standard second-line antituberculous drugs. The 
results of that study are to be expected soon [NCT00425113].
Metronidazole is generally well tolerated. Adverse reactions include reversible neutropenia, 
minor gastrointestinal side effects, metallic taste, vaginal and urethral burning, and 
darkening of the urine. Central nervous system side effects include ataxia, vertigo, 
peripheral neuropathy and headache [50]. Metronidazole can produce a reaction similar 
to that of disulfiram when administered to patients using alcohol because the interaction 
between metronidazole and ethanol leads to a toxic accumulation of acetaldehyde in the 
blood [51]. Care should be taken in using this drug for alcohol abuse patients.
TETRACYCLINES
Doxycycline and tigecycline belong to the tetracycline group of antimicrobials, which 
exhibit a broad spectrum of activity against different pathogens, including Gram-positive 
and Gram-negative bacteria [52]. Tetracyclines are bacteriostatic and act by binding to 
the bacterial 30S ribosomal subunit and inhibiting protein synthesis. Tetracyclines are 
effective in the treatment of a wide range of infectious diseases like community-acquired 
respiratory tract infection, sexually transmitted diseases and skin conditions [52].
Doxycycline is an antibiotic with broad spectrum matrix metalloproteinase (MMP) 
inhibitory activity [53]. It not only reduces the expression of MMPs, thereby minimising 
tissue damage in TB, but also suppresses mycobacterial growth. Because doxycycline 
is safe, cheap and almost universally available, it may represent a new adjunctive 
therapy to improve outcomes and reduce mortality for TB [54]. Tigecycline (GAR-936) 
is a new semisynthetic glycylcycline (tetracyclines analogue) and is effective against 
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intra-abdominal, skin and soft-tissue infections caused by staphylococci, enterococci 
or streptococci, as well as most enterobacteriaceae and anaerobic pathogens [52, 55]. 
Tigecycline is effective against rapid-growing mycobacteria (M. fortuitum, M. chelonae 
and M. abscessus) but showed no activity against more slow-growing mycobacteria (M. 
tuberculosis) [55, 56].
In vitro studies 
Doxycycline suppressed MMP1 and MMP3 as well as TNFα secretion from primary human 
macrophages infected with M. tuberculosis at 72 h in a dose-dependent manner. This drug 
is bacteriostatic to M. tuberculosis clinical isolates with an MIC of 2.5 µg/ml [54]. In 69 MDR-
TB isolates obtained from patients in the Samara region of Russia, 5 (7.4%) isolates were 
resistant to doxycycline [57]. In vitro MIC values of tigecycline against clinical isolates of M. 
tuberculosis were as high as 8-64 µg/ml [58].
In vivo studies 
Doxycycline decreased mycobacterial replication in infected guinea pigs but showed no 
effect on MMP activity. In a dose of 5 and 20 mg/kg, doxycycline monotherapy suppressed 
lung CFU at 10 weeks in a dose-dependent manner. The results showed that doxycycline 
improved the outcome for TB by acting directly on mycobacterial proliferation rather than 
on MMP activity [54]. No publications mentioned the antimicrobial activity of tigecycline 
in vivo.
Clinical studies
Doxycycline is available in oral form, unlike tigecycline, which is only available as an 
injectable [52]. This drug is absorbed well from the gastrointestinal tract, with bioavailability 
ranging between 75-100% [52]. It is absorbed quickly and reaches its maximum serum 
concentration (Cmax) within 4 h [52]. Cmax and area under the plasma concentration time 
curve (AUC) of tigecycline are proportional with the dose [52, 55]. In epithelial lining fluid 
the area under the curve of tigecycline was 2.28 µg. h/ml, which is higher than that of 
serum, 1.73±0.64 µg. h/ml [59]. Doxycycline is lipophilic and penetrates well into tissues, 
especially the brain, eye, prostate and intestinal epithelia [52]. Higher concentrations of 
doxycycline are found also in the kidney and liver [60]. Tigecycline has a large volume of 
distribution, 710L/kg [61]. It shows good penetration into tissues like bones, skin, liver and 
lung [52]. The protein binding of doxycycline is between 60-95%, while that of tigecycline 
ranges between 71-89% [52].
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Tigecycline has a half-life of 15-36 h, which is greater than the 12 h half-life of doxycycline 
[52,  59]. No more than 15% of tigecycline is excreted in the urine in unchanged form [52, 
62]. About 30-40% of doxycycline is excreted unchanged in the urine [52].
Doxycycline is safe in humans and may suppress immunopathologic MMPs, thereby 
reducing tissue damage in TB patients using a low dose (20 mg twice daily). It may achieve 
sufficient concentration in the lung interstitium to decrease the growth of M. tuberculosis 
and modulate MMP activity and expression [54]. No clinical data are available for the 
potential use of tigecycline for the treatment of MDR-TB in humans. The most common 
side effects of doxycycline are gastrointestinal problems and skin reactions [63]. In a 
study with healthy subjects, tigecycline had no serious side effects except for nausea and 
vomiting, which were dose-related [62].
DISULFIRAM
Disulfiram (tetraethylthiuram disulfide, DSF) has been used orally in the clinical treatment 
of alcoholism since 1949. DSF is a prodrug and is enzymatically metabolised in the blood 
to metabolites, primarily diethyldithiocarbamate (DDC or DETC) within 4 min [64,  65]. 
DSF and DDC exhibit growth-inhibitory activity against bacteria, fungi, protozoa and 
viruses. DSF is effective against MDR/XDR-TB and exhibits bactericidal activity in vivo and 
in vitro [64]. The mechanism of action of DDC against M. tuberculosis has been reported as 
inhibition of beta-class carbonic anhydrases (beta-CAs) from M. tuberculosis [66]. 
In vitro studies 
Peripheral blood mononuclear cells (PBMC) of healthy and HIV subjects were preincubated 
with 100-1000 ng /ml of DDC and then infected with M. tuberculosis H37Rv. DDC reduced 
the CFU number of these intracellularly-growing mycobacteria. DDC also enhances the 
antimycobacterial activity of monocyte-derived macrophages from healthy volunteers 
injected with 5mg/kg body weight DDC ex vivo. DDC can enhance macrophage maturation 
by the induction of 1, 25-(OH)2 cholecalciferol (vitamin D3) [67]. Vitamin D3 may play an 
important role in the pathological process of tuberculosis by downregulating the levels 
of matrix metalloproteinases (MMPs) and upregulating the levels of tissue inhibitor of 
metalloproteinase (TIMPs) [68]. Vitamin D3 also mediates the production of cathelicidin, 
which is a monocyte-macrophage peptide with significant anti-TB activity, in the context 
of Toll-like receptor 2/1-ligand activation [69]. An in vitro study showed that DETC was 
highly active against tubercle bacilli with MIC of 8 µg /ml [65].
DSF and DDC showed antitubercular activity against more than 40 clinical isolates of M. 
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tuberculosis, including MDR/XDR-TB strains. The MIC90s of DSF and DDC against clinical 
isolates were 1.56 and 3.13 µg/ml respectively. They also show bactericidal activity against 
intracellular M. tuberculosis in human monocyte leukemia cell line (THP-1) at 6-30 µg/ml 
and 10-30 µg/ml respectively [64]. Since no cross resistance of DSF and DDC with other 
anti-TB drugs was observed, these compounds may be of potential value for future 
regimens against MDR/XDR-TB [64].  
In vivo studies 
DSF kills M. tuberculosis at (80-160) µg/kg in a mouse model with chronic TB [64]. DETC 
enhances the activity of pyrazinamide and rifampin twofold when co-administered in 
mice at 100 mg/kg, showing activity against persisters of M. tuberculosis [65].
Clinical studies 
DSF is rapidly and completely absorbed following oral administration, and is quickly 
reduced to DDC. DDC is metabolised to diethylamine, carbon disulfide (CS2), DDC methyl 
ester, DDC glucuronide and DDC sulfate; a small amount of DDC is reoxidised to DSF. 
DSF, DDC and CS2 are widely distributed throughout the body in lipids of various tissues, 
and the highest levels of these compounds are found in skeletal muscle [70]. Humans 
eliminate more than 90% of orally administered DSF within 3 days by renal clearance as 
DDC and DDC glucuronide, to a small extent as DDC sulfate, and via the breath as CS2 
[70]. Few publications showed the activity of DSF or its metabolites against TB. Only one 
study found that DDC reduces the incidence of infections in HIV co-infected TB patients, 
probably by stimulating the antimicrobial activity of mononuclear phagocytes [67].
The side effects of disulfiram are mainly on the central nervous system and include 
psychosis or confusional state that occurs in the early period of DSF therapy with higher 
dosages of DSF (500 mg/day). Another serious side effect is peripheral neuropathy. All 
these side effects were reversible [71]. Rarely, DSF can cause fatal hepatitis [71].
CO-TRIMOXAZOLE
Co-trimoxazole (SXT) is a synergistic combination of two antimicrobial agents: trimethoprim 
(TMP) and sulfamethoxazole (SMX). Its mechanism of action is interference with folic acid 
synthesis of bacteria. SXT is used predominantly to treat urinary tract infections and for 
prophylaxis and treatment of Pneumocystis jiroveci pneumonia (PCP) in HIV patients [72, 
73]. There is ongoing debate about the use of SXT for the treatment of TB. Some studies 
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mention that only SMX was effective against M. tuberculosis, while TMP is not [74, 75].
In vitro studies
M. tuberculosis strains appeared to be susceptible to SXT in 43 of 44 (98%) isolates tested. 
These isolates were sensitive to TMP-SMX at MIC ≤1/19 µg/ml [74]. Another study showed 
that SMX inhibits 80% and 99% growth of all 117 clinical isolates at MIC 19 mg/l and 38 
mg/l respectively [76]. Drug susceptibility testing in a recent study mentioned that MICs 
values of SMX for M. tuberculosis ranged between 4.75-25 µg/ml [77]. In 7H9 broth, M. 
tuberculosis was susceptible to SMX; MIC90 was 8 µg/ ml. In that study SMX achieved an 
excellent activity against M. tuberculosis [78]. One in vitro study showed that M. tuberculosis 
strain H37Rv was susceptible to SMX and not to TMP at MIC of 8.5 µg/ml. When SXT was 
added to an isoniazid- or rifampin-treated M. tuberculosis culture isolate, SMX with and 
without TMP was efficient at killing and preventing its growth, thereby preventing the 
emergence of drug resistance [79].
In an in vitro study, M. tuberculosis strains were exposed to either a TMP/SMX combination, 
SMX and TMP alone, or SMX in combination with first-line TB drugs (isoniazid, rifampicin 
and ethambutol). TMP had a negligible effect on the growth of M. tuberculosis, while SMX 
inhibited 80% of the growth at 4.75 mg/L. There was no synergistic activity between the 
TMP and SMX combination, but an additive effect was observed. SMX had a synergistic 
effect combined with rifampicin, an additive effect combined with ethambutol, and no 
effect with isoniazid [80].
Clinical studies 
The total absorption of SMX is 85-90%. Concentrations of the non-protein-bound fraction 
of SMX to TMP in plasma varied between subjects, ranging from 1:5 to 1:40 [81]. The 
explanation could be that SMX has a smaller volume of distribution (10-20L) than TMP 
(69-133L). In the blood, SMX is bound to plasma proteins to an extent of 58-66% (34-
42% free) [81, 82]. SMX is well distributed in most body fluids and also in cerebrospinal 
fluid, so it may be a good candidate for treating TB meningitis [81]. Concentrations of SMX 
in sputum, middle-ear fluid and paranasal sinus fluid are about 20-27% of serum, and 
in bronchial secretion 60-100% of those in serum [83]. SXT penetrates epithelial lining 
fluid easily because it is lipophilic and inflammation-independent [84, 85]. Following 
distribution of SMX, it is partially acetylated and glucuronide-conjugated in the liver [86]. 
SMX excretions are 60-65% acetyl derivative, and 15% appear as glucuronides. These 
metabolites constitute 70% of total SMX in urine and 20-35% in plasma [81]. 
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The plasma half-life of SMX is 9 hours [81]. 
Limited data are available on the pharmacokinetic parameters of SXT in MDR-TB patients. 
Only one study described the PK parameters after receiving 480 mg and 960 mg of 
co-trimoxazole. PK parameters of SMX in TB patients including area under the curve, 
clearance and volume of distribution are lower than the values observed in patients with 
other indications. These patients seem to display a consistent PK profile for SMX [77]. 
Adherence and tolerance to the drug was good when SXT was used in a daily dose of 960 
mg as prophylaxis to reduce the mortality in adults with HIV infection and TB, by preventing 
opportunistic infections. The rates of occurrence of one or several side effects that could 
be due to SXT were similar in the placebo group (n=372) and in the co-trimoxazole group 
(n=371) [87]. An SXT dose of 960 mg/day added to routine care improved the survival of 
HIV-positive TB patients dramatically; SXT prophylaxis should therefore be added to the 
routine care of HIV-positive TB patients [88].
In five clinical studies summarised in one study [73], co-trimoxazole was safe, feasible and 
effective in the prophylactic treatment of HIV patients with TB; it has beneficial effects like 
lower mortality, fewer hospital visits, weight gain, improved CD4 cell counts and reduced 
plasma HIV in PCP, malaria and other bacterial (pneumococcal) airway infections. The 
impact on infections with M. tuberculosis was not considered in these studies.
In general, TMP-SMX is a safe medication and is tolerated well. The most common side 
effects include gastrointestinal intolerance, nausea, vomiting, anorexia and diarrhea [86]. 
Possible side effects in the blood are hyperkalemia, slight increase in serum creatinine 
levels (not representing loss of glomerular filtration but rather reversible decrease in 
tubular excretion of the creatinine molecule) and hypernatremia. These effects occur 
especially in patients with renal dysfunction [86, 89, 90]. Hematological abnormalities 
include leucopenia, agranulocytosis and thrombocytopenia, hemolytic and aplastic 
anemia [91].
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DISCUSSION
The need for new drugs to improve the treatment of patients with MDR-TB has received 
much attention. These patients are currently treated with a combination of second-line 
drugs that are more expensive, more toxic and less effective than the drugs used in 
standard therapy, and which have a much longer treatment duration than those for drug-
susceptible TB patients. This often results in poor outcomes. Exploring the antimicrobial 
activity of drugs that are already available on the market would therefore be a tremendous 
asset. This review identifies the pharmacokinetics and pharmacodynamics and the in vitro, 
in vivo and clinical data of these drugs. 
Based on the in vitro, in vivo and clinical data of the drugs discussed in this review, 
thioridazine, doxycycline, metronidazole and co-trimoxazole were selected as candidate 
drugs for possible use in MDR-TB. They are effective either against metabolically active, 
fast-replicating, or metabolically inactive, non-replicating phenotypes of M. tuberculosis 
(dormant state). These drugs also have favourable pharmacokinetics, like CNS and CSF 
penetration, that may be useful for the treatment of TB meningitis. 
However, thioridazine has no activity against rapidly-replicating metabolically active M. 
tuberculosis, such as inactive cavitary pulmonary TB, because of the poor penetration of 
this drug into the cavities; it thus lacks efficacy against this stage of TB. The same is true 
for metronidazole, which is predominantly active under anaerobic conditions, although 
this drug appears to have activity against dormant M. tuberculosis. Compounds of similar 
structure to metronidazole have been shown to have potent antitubercular activity in 
vitro and in vivo, like CG17341 and PA 824 [92]. Metronidazole could thus be used as a 
lead compound for the synthesis of new drugs against MDR-TB, especially for dormant 
organisms. Doxycycline has bacteriostatic but no bactericidal effect against M. tuberculosis, 
so it isn’t the first choice to develop further.
According to the pros and cons of the selected drugs mentioned in detail in the Results 
section, co-trimoxazole could be the promising drug for treating MDR-TB because of its 
consistent pharmacokinetic profile in combination with other anti-TB drugs. It is an easy-
to-administer, cheap, well-tolerated and safe antimicrobial agent. It has also encouraging 
activity in vitro. The other compounds discussed here have some limitations that may 
restrict their uses for treatment of MDR-TB. Because of the fatal outcome of a disulfiram-
alcohol reaction, this drug should not be administered to TB patients who are alcohol 
abusers. Tigecycline is administered only parenterally and is not effective against more 
slow- growing mycobacteria such as M. tuberculosis. 
Our review has several strengths. We conducted a very comprehensive literature search 
by exploring electronic databases to get information about anti-TB activity of the selected 
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drugs. These drugs are not listed in WHO guidelines but they have in vivo, in vitro or clinical 
activity against M. tuberculosis, and no previous review mentions their antimicrobial 
activity in the treatment of MDR-TB. Hence this review could be an interesting starting 
point for further research in the future.
This review has also some limitations. The review was restricted to only six antimicrobial 
drugs and does not discuss other new or already-available drugs that have anti-TB 
activity. Most published articles provide insufficient data for the role of these drugs in 
the treatment of tuberculosis. We excluded those articles not available in the English 
language, even though articles in other languages could have important data. Because 
limited MDR-TB clinical data for these drugs are available, a lack of dose selection studies 
was observed. We did however mention the doses and response to these drugs for TB and 
XDR-TB patients in clinical studies if they weren’t available for MDR-TB patients.
There is only limited antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) information 
available for the drugs discussed here. This could be an obstacle for finding suitable doses 
and predicting their efficacy in the treatment of MDR-TB patients. Antimicrobial PK/PD 
derived in preclinical PK/PD models like the hollow-fibre infection model and the mouse 
models, as well as additional clinical trials, do offer the possibility to study toxicity and to 
determine duration of therapy. These will be important steps in the further development 
of these drugs for use in MDR-TB. 
A clinical prospective study should be conducted to evaluate pharmacokinetic parameters 
and tolerance in order to find the suitable dose for the treatment of MDR-TB patients in 
a phase II study. In a phase III study, the clinical efficacy and long-term safety of the drug 
should be investigated by comparing the sterilising activities of the candidate alone and 
when substituted for one standard anti-TB drug. These approaches are essential for an 
efficient clinical development of potential antimicrobial drugs for TB treatment.
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ABSTRACT
Co-trimoxazole (SXT), a combination of sulfamethoxazole (SMX) and trimethoprim has 
shown in vitro activity against Mycobacterium tuberculosis. However, the pharmacokinetic 
(PK) and pharmacodynamic (PD) parameters of SXT in multidrug-resistant (MDR) 
tuberculosis (TB) are so far lacking. Therefore, we evaluated the PK and drug susceptibility 
along with its tolerability during treatment.
Based on drug-susceptibility testing MDR-TB patients received SXT as a part of their 
MDR treatment. The PK parameters of SMX, the effective component of SXT against 
Mycobacterium tuberculosis were evaluated. The ratio of AUC0-24h/MIC was used as the 
best PK/PD parameter to predict the efficacy of SMX. Adverse effects of SXT were also 
evaluated. 
Ten patients with MDR-TB (one of whom had XDR-TB) received 480 mg of SXT with median 
dose of 6.5 mg/kg of SXT (Range, 6.1-6.8) qd for a median treatment period of 381 days 
(Range, 129-465). In two patients, the dose was escalated to 960 mg. ƒAUC0-24/MIC of 
SMX exceeded 25 in only one patient. SXT was safe and well tolerated except for one 
patient who had gastrointestinal side effects after receiving 960 mg of SXT. Additional 
studies are needed to find the PK/PD targets and consequently to set the optimal dose of 
SXT for MDR-TB treatment.
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Multidrug-resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) are 
emerging in many areas around the world [1]. Also the susceptibility of Mycobacterium 
tuberculosis against current antituberculosis (anti-TB) drugs has decreased and therefore 
the treatment of MDR-TB has become increasingly complicated [2]. Consequently, there 
is an urgent need for new effective drugs with a minimum of toxicity. An old, inexpensive 
and well-tolerated drug like co-trimoxazole (SXT), which is registered for other indications 
than TB, could be a new effective agent for the treatment of MDR and XDR-TB [3].
SXT is a combination of trimethoprim (TMP) and sulfamethoxazole (SMX) in a ratio of 1:5. It 
is a potent antibacterial drug against a variety of pathogens causing infections in humans. 
SXT is currently used in the treatment of urinary tract infections, otitis media, shigellosis, 
chronic bronchitis and pneumocystis carinii pneumonitis [4]. 
SXT shows concentration-independent or time dependent killing. Therefore, the ratio of 
area under the free concentration-time curve (ƒAUC) from 0 to 24 h relative to the minimal 
inhibitory concentration (MIC) is considered to be the important pharmacokinetic (PK)/ 
pharmcodynamic (PD) parameter to predict the efficacy of SXT [5]. Very little is known 
about the PD of SXT [5]. There are only few publications on the PK parameters of SXT 
of which none in TB patients (table1) [6-9]. Only two studies investigated the in vitro 
susceptibility of SXT against M. tuberculosis and showed promising results [3, 10]. From 
these studies it could be concluded that only SMX was effective against M. tuberculosis 
and TMP is not [3, 10,11]. One study mentioned AUC/MIC ratio of SXT that had to be 
exceeded 25 for effective treatment of melioidosis caused by Burkholderia pseudomallei 
[12] .The lack of data is likely due to the fact that SXT is an old drug and in vitro evaluation 
of PK/PD parameters in infection models is rather new.
In general, SXT is a safe and well-tolerated drug. Gastrointestinal complications including 
nausea, vomiting, anorexia and diarrhea are the most common adverse effects of SMX [13, 
14]. Renal side effects including hyperkalemia, slight increase in the serum creatinine level 
and hyponatremia occur especially in patients with renal dysfunction [15, 14,16]. Other side 
effects reported are hematological side effects like megalo-blastic anemia, leucopenia, 
thrombocytopenia and aplastic anemia in patients with preexisting megaloblastic 
anemia or deficiencies in folic acid stores (alcoholics, malnourished patients and pregnant 
women) [17]. 
Although SXT has been administered to TB patients, data is very scarce and its role in TB 
treatment is still not yet clear. The objective of this study was to evaluate PK, PD and PK/
PD parameters and safety/tolerability of SXT in MDR-TB patients
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TABLE1- Pharmacokinetic parameters of SMX for the treatment of different infections from previous studies







Single dose 1.6 g 
orally 10.0±1.1 N/A N/A 1295±823 [9]
Normal 
meninges 9
25 mg/kg over 
120 mini.v. 9.8±1.5 0.30±0.04 0.36±0.03 1,160±103 [6]
AIDS 8 75 mg/kgdaily (IV) 15.5±7.4 0.5± 0.3 0.40±0.12 N/A [7]





Data are presented as n, mean ±SD or median (range), t1/2: half- life; VD: volume of distribution; AUC: area under 
the concentration time curve; NA: not available
PATIENTS AND METHODS
Patients 
MDR-TB patients who were referred to the Tuberculosis Center Beatrixoord of the University 
Medical Center Groningen (Groningen, The Netherlands) between the 1st January 2006 and 
the 1st July 2012 and for whom drug susceptibility testing (DST) for SXT was performed, 
were eligible for evaluation. Age, gender, weight, ethnicity, underlying disease, minimum 
inhibitory concentration (MIC) of the Mycobacterium tuberculosis isolate, localization 
of TB, other anti-TB medications, duration of treatment with SXT and the total anti-TB 
regimen administration were recorded for MDR-TB patients that received SXT. Patients 
were subjected to routine medical care without specific study-related interventions. We 
describe patient data obtained during usual care, and therefore, no ethical clearance was 
required under Dutch Law (WMO).
Pharmacokinetics and Pharmacodynamics
Blood samples were only evaluated when obtained at steady state which was after at least 
three days of administration of SXT [18]. They were collected before and at 1, 2, 3, 4 and 8 
h after SXT administration. 
The concentrations of SMX in human plasma samples were analyzed in the laboratory of 
Clinical Toxicology and Drugs Analysis of the Department of Hospital and Clinical Pharmacy 
at the University Medical Center Groningen by a validated liquid chromatography-
tandem mass spectrometry (LC-MS/MS). In brief, 5 µl of each plasma sample was mixed 
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with 750 µL precipitation reagent (methanol and acetonitrile 4:21, v/v). From the clear 
upper layer 5 µL was injected on a 50 mm×2.1 mm reversed phase C18, 5-μm analytical 
column (HyPurity Aquastar, Interscience Breda, The Netherlands) for chromatographic 
separation. The detector was operated in electrospray positive ionization mode and 
performed selected reaction monitoring (SRM) as scanning mode. The transition of m/z 
254.1-155.9 (collision energy 25 eV) for SMX was measured with scan width of 0.5m/z. The 
recoveries ranged from 97.7% to 102.9%, depending on the concentration. The accuracy 
was between 97.7% and 102.9% for SMX, depending on the concentration level. The intra- 
and inter assay coefficients of variation were less than 5.1 % over the ranges of 5 to 100 
mg/L. The lower limit of quantization was 5 mg/ L.                
PK parameters of SMX, including AUC0-24h, volume of distribution (Vd), clearance (Cl) and 
half-life (t ½) were determined with a standard non-compartmental PK method using the 
KINFIT module of MW/Pharm 3.60 (Mediware, Groningen, The Netherlands). The AUC0-24 
in plasma was calculated according to the log –linear trapezoidal rule. In this case, the 
concentration of SMX at 24 hours after oral administration was estimated to be equal to 
its concentrations at zero time (before administration of the dose).
The free non-protein bound fraction of antibacterial drug is responsible for the clinical 
effect of these drugs [19]. The free AUC0-24 (ƒ AUC0-24) values estimated by multiplying 
the total AUC0-24 values by the fraction unbound of 0.23 which was retrieved from an 
earlier study [19]. Free-drug AUC0-24/MIC ratios were calculated by dividing the ƒ AUC0-24 
by the MIC value for SMX. 
A one compartmental PK population model (POP-PK) of SMX with first order absorption 
without lag time was developed using an iterative two-stage Bayesian procedure (MW/
Pharm 3.60) starting with pharmacokinetic estimates from previous study [8]. 
The individual PK parameters of each patient were calculated using KINFIT. KINPOP is used 
to calculate the parameters of the MDR-TB patients based on the individual concentrations 
of SMX and patient characteristics like body weight, age, gender and creatinine clearance 
[20].  
To determine the MIC values, the patientsۥ M. tuberculosis isolates were subjected to 
DST which was performed on the Middelbrook 7H10 agar dilution method at the Dutch 
national Mycobacterium Reference Laboratory (National Institute for Public Health and 
the Environment, RIVM) [21]. In accordance with European Committee on Antimicrobial 
Susceptibility Testing, the MIC of SXT is expressed as TMP: SMX in the ratio 1: 19.
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Safety
The safety of SXT during TB treatment was evaluated by assessing the reported side effects 
of SXT retrospectively using a standardized data abstraction form from the Tuberculosis 
Centre Beatrixoord. Specific attention was paid to the side effects that could be caused by 
SXT like gastrointestinal side effects (nausea, vomiting and diarrhea), hepatotoxicity, and 
anemia and blood count abnormalities [22]. 
Hepatic injury was defined as elevation in one of the hepatic enzymes five times the 
upper limit of normal during the treatment with SXT (grade 3 common toxicity criteria 
(CTC)). These enzymes include aspartate aminotransferase (ASAT> 200 U.L -1), alanine 
aminotransferase (ALAT>225 U.L -1) and gamma-glutamyl transpeptidase (GGT>200-275 
U.L-1) [23]. For other side effects the defined normal values were: anemia (hemoglobin 
normal range 7.5 – 9.9 mmol/L (female) and 8.7 – 10.6 mmol/L (male)), leukocyte count 
(4 × 109/L) and platelet count (150  -  350  x109 /L). The adverse drug reactions (ADR) in 
patients on multiple drug regimens like MDR-TB patients would require a standard 
causality assessment tool (Naranjo algorithm) [24]. Using this tool, we considered that 
SXT is definitely the cause of ADR if the score ≥ 9, probable if 5 to 8, possible if 1 to 4, and 
doubtful if the sore ≤ 0.
Statistics
Wilcoxon signed-rank test was employed in the statistical analysis when the data were 
not normally distributed. The POP-PK model was cross validated by developing a POP-PK 
model based on n-1 and by predicting the AUC 0-24h of the subject left out during the 
model development. The correlation between the predicted based on the POP-PK model 
and calculated AUC0-24h was tested by means of a Bland and Altman analysis.
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For 17 MDR-TB patients DST for SXT was performed. Only in ten patients SXT was used 
as part of their TB regimen because DST showed that isolates were susceptible to SXT. 
In the other cases resistance to SXT (n=4) or more conventional TB drugs could be used 
(n=3) (Table 2). In general, these TB patients were relative young with a median age of 
29 years (Inter Quartile Range (IQR), 24-31years), and had a relatively low median body 
mass index (calculated as weight in kilograms divided by the square of height in meters) 
of 21.1(IQR, 19.1-23.6). The resistance of Mycobacterium tuberculosis to at least isoniazide 
and rifampicin was diagnosed by culture.  Eight patients had Pulmonary TB as the most 
common diagnosis in MDR-TB patients, one patient had urogenital TB and one had both 
pulmonary and extra pulmonary TB. SXT was prescribed as 480 mg daily. This equals to 
a median dose of 6.5 mg/kg (IQR, 6.1-6.8) in various combination regimens for a median 
period of 381 (129-465) days. The daily dose of SXT was increased arbitrary to 960 mg 
which equals to 14 and 13 mg/kg in two patients because of low level of SXT in blood 
related to MIC in these patients.  All of the patients had a negative history for underlying 
diseases except for one patient who had diabetes mellitus. None were diagnosed with 
co-infection with human immunodeficiency virus. Eight of the 10 patients successfully 
completed the treatment with no signs of recurrence. Two patients are still on treatment at 
the time of writing this report; sputum culture was converted and they are in good clinical 
conditions. The clinical data of all 10 patients are shown in Table 3. DST was evaluated in 
all MDR-TB patients. Susceptibility and resistance of M. tuberculosis against anti-TB drugs 
are shown in Table 2.
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TABLE 2-Susceptibility and Resistance to anti TB drugs (n=17)
Group 1: First-line oral agents  R S   I
Isoniazide 17 (100)   
Ethambutol 14 (82.4) 2 (11.8)                           1 (5.9)
Rifampicin 17 (100)   
Pyrazinamide 9 (53) 8 (47)  
Rifabutine 13 (76.5) 3 (17.6)                          1 (5.9)
Group 2: Injectable anti-TB-medication      
Amikacine 7 (41.2) 10 (58.8)  
Kanamycin 2 (11.8) 4 (23.5)  
Streptomycin 15 (88.2) 2 (11.8)  
Capreomycin 5 (29.4) 10 (58.8)  
Group 3: Fluoroquinolones    
Ofloxacin 1 (5.9)   
Moxifloxacin 3 (17.6) 13 (76.5)                   1 (5.9)
Ciprofloxacin 4 (23.5) 12 (70.6)  
Group 4: Other bacteriostatic second Iine agents
Protionamide 4 (23.5) 12 (70.6)  
Cycloserine 1 (5.9) 7 (41.2)  
Group 5: Antituberculosis drugs with unclear efficacy
Linezolid 13 (76.5) 3 (17.6)  
Clofazimine  11 (64.7)  
Clarithromycin 2 (11.8) 5 (29.4)  
Augmentin 9 (53) 4 (23.5)  
Imipenem 2 (11.8)  
Others 
Co-trimoxazole 4 (23.5) 13 (76.5)  
Ertapenem 7 (41.2)  
Tigecycline 7 (41.2) 1 (5.9)  
Meropenem 1 (5.9)   
R: Resistance; S: susceptibility; I: intermediate susceptibility. Data are presented as absolute values (%) of MDR-TB 
patients susceptible, resistant and intermediately-susceptible to Anti-TB drug
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#Patients still on treatment. BMI: body surface area; m: male; f: female; Anti-TB; antituberculosis; E: ethambutol; 
SXT; Z: pyrazinamide; KM: kanamycin; AM: amikacin; CM: capreomycin; CPX: ciprofloxacin; CS: cycloserine; CLM; 
clarithromycin; MOX: moxifloxacin; CFZ:  clofazimine; PTH: prothionamide; Doxy: doxycycline, ERTA: ertapenem; 
amoxicillin+clavulanic acid (Augmentin): AMX/CL; LZD: linezolid.
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Pharmacokinetics (PK) and pharmacodynamics (PD)
The steady state PK parameters of SMX could be evaluated in only 8 of total 10 patients 
receiving 480 mg SXT once daily because in the other two patients no plasma sampling 
was performed during the treatment period with SXT. The PK parameters are summarized 
in Table 4. The observed plasma concentration- time curves of SMX were obtained from 
the patients after receiving 480 mg of SXT; these are shown in figure 1. 
TABLE 4- Pharmacokinetic parameters of SMX at steady state after oral administration of 480 mg of SXT (n=8)
Pharmacokinetic parameter SMX (400 mg)
AUC 0-24 (mg.h.liter-1 ) 371.5 (360-574.8)
Cl  (ml/min/kg) 0.19 (0.14-0.25)
V (L/kg ) 0.15 (0.13-0.22)
t ½ (h) 10.1 (8.7 -10.8)
Pharmacokinetic data are presented as median (interquartile range). AUC 0-24: area under the concentration-
time curve up to 24 h post dosage; Cl: clearance; V: volume of distribution; t ½: half-life.
FIGURE 1-Plasma concentration-time curves of Sulfamethoxazole (n=8)
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The parameters of POP-PK model of SMX are shown in Table 5. The cross validation of 
this model showed that the geometric mean values of the POP-PK model (n-1) were Cl 
(1.28 ± 0.52) L/h/1.85 m2, Vd (0.22± 0.03) L/Kg LBMc, Ka-po (0.44±0.18), these results were 
not different from the POP-PK model (Table 5). The individual difference between the 
predicted based on POP-PK model and calculated values of AUC0-24 was underestimated 
by a median percentage of -0.7 (Range, -6.2-2.8). The agreement between predicted with 
the POP-PK and calculated AUC0-24h of SMX is shown in figure 2. This figure shows that all 
the values of AUC were within the agreement only one was outside this agreement. The 
median percentage of difference between the predicted based on POP-PK (n-1) model 
and calculated values of AUC0-24   was -3.92 (Range, -6.3 -1.7). 
The drug susceptibility testing shows that MICs values of SMX for M. tuberculosis varied 
with median ranges of 9.5 (IQR, 4.8-25) mg/L.
 The ratios of ƒAUC0-24h/MIC of SMX in each patient are presented in Table 6. The geometric 
means of AUC/MIC and ƒAUC0-24h/MIC ratios after receiving 480 mg for SMX were 48.4 
(IQR, 34.8-71.3) and 11.1 (IQR, 8 -16.4) respectively. One of the eight patients that received 
480 mg of SXT had ƒAUC0-24h/MIC ratio of SMX greater than 25. 
TABLE 5-Population pharmacokinetic model parameter values of SMX (n=8)
Parameter Values
Cl (L.h/1.85 m 2) 1.14 ± 0.43
Vd (L. Kg-1 LbMc) 0.24 ± 0.05
Ka (h-1) 0.43 ± 0.17
F 1
Data are expressed as geometric mean ± standard deviation. Cl: apparent clearance; Vd: volume of distribution; 
Ka: absorption rate constant; F: bioavailability.
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FIGURE 2-Bland-Altman plot showing the agreement between predicted and calculated area under the concentration-time curve up 
to 24 h post-dosage(AUC0-24) of Sulfamethoxazole




AUC0-24 (mg .h/L)         
400 mg SMX
ƒAUC0-24/MIC       
400 mg SMX
AUC0-24 (mg 
.h/L) 800 mg 
SMX
ƒAUC0-24/
MIC       
800 mg 
SMX
1 25 376 3 774 7
2 4.75 297 14 -  -
5 9.5 658 16 991 24
6 25 509 5 - -
7 4.75 597 29 - -
8 4.75 367 18 - -
9 19 752 9 - -
10 4.75 281 14 - -
AUC 0-24: area under the concentration-time curve up to 24 h post dosage; MIC: minimum inhibitory concentration; 
ƒAUC0-24/MIC: protein unbound (free) AUC from 0 to 24 h relative to the minimal inhibitory concentration (MIC).
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In general, SXT was well tolerated. However, there were some mild side effects including 
abdominal complaints with diarrhea and vomiting in one patient (Naranjo score=4). 
Elevations in hepatic enzymes (ASAT and ALAT) were observed in two patients that are 
receiving 480 and 960 mg of SXT respectively (Naranjo scores= 5). In these two patients 
the values of ALAT during treatment with 480 mg were 47.50 and 48 U.L -1 (baseline 29) 
and with 960 mg of SXT were 46 and 71 U.L -1 (baseline 43). The values of ASAT after 
receiving 480 and 960 mg of SXT were 48 and 99 U.L -1 respectively compared with baseline 
35. Although the hepatic enzymes were two times higher than base line, the values of 
ASAT and ALAT did not exceed 5 times the upper limit of normal. The median hemoglobin 
level in patients before treatment with 480 mg SXT was 7.6 mmol/L (range: 7.6 to 8 
mmol/L) and during treatment was 7mmol/L (range: 6.6- to 7.2 mmol/L); the difference 
was significant (P=0.002) but probably, clinically not relevant. The value of Naranjo score 
for low hemoglobin level is 3 or 4. One patient developed leucocytopenia after receiving 
480 and 960 mg of SXT. Leucocyte counts were 2.2×109/L and 3.2 ×109/L respectively in 
comparison to a baseline value of 4.2 (Naranjo score=3). Besides, one patient developed 
mild thrombocytopenia with a thrombocyte count of 146 x109 /L and of 247 at baseline 
(Naranjo score = 3). 
DISCUSSION
No earlier study described the PK, PD and PK/PD parameters of SXT in MDR-TB patients. 
It is interesting is that the PK parameters of SMX in TB patients including AUC 0-24h, Vd and 
Cl are lower than the values observed in patients with meningitis, HIV infections or those 
who suffering from bacterial skin infection (Table 1) [6-9].  Low drug exposure may be 
explained by decreased intestinal absorption resulting in low serum concentrations of 
antituberculous drugs.  Other factors such as alcohol abuse, smoking, weight loss, albumin 
and hemoglobin could be the possible reasons for reduced permeability via paracellular 
intestinal transport [25]. To further explore the PK parameters in MDR-TB patients, we 
made a population model. This model showed no significant difference between the 
calculated and predicted AUC according to Bland-Altman analysis and this difference was 
also statistically insignificant (P=0.78). Thus, MDR-TB patients seem to display a consistent 
PK profile for SMX. Therefore, this developed model could be used to assess drug exposure 
in a prospective study to evaluate the safety and efficacy and find the suitable dose of SXT 
as part of a TB-regimen. 
The MIC value of SMX in this study was in accordance with previous study that mentioned 
that SMX inhibits 80% growth of all 117 isolates at an MIC 19 mg/L [10].
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The PK-PD parameter (AUC0-24/MIC) best predicting of SMX efficacy has not been firmly 
established. According to an earlier single study, the ƒ AUC 0-24/MIC of SMX had to 
exceed 25 for adequate treatment of melioidiosis [12]. From the results, it can be seen 
that only in 1 of 8 patients, ƒ AUC 0-24/MIC ratio of SMX was > 25. However, this ratio 
could be lower than 25 and still be effective in TB treatment. Especially the magnitude 
of this parameter may vary for different bacterial species. For example, the AUC0-24/MIC 
ratio for fluoroquinolone is different against Pseudomonas aeruginosa and other gram-
negative bacilli [26]. The lower ratio might be acceptable in patients receiving multidrug 
treatment for MDR-TB. Other drugs might decrease this ratio as shown in a murine aerosol 
infection model from previous study in which the AUC0-24/MIC ratio of rifampicin that 
correlated with efficacy decreased when administered in combination with moxifloxacine 
[27]. Therefore, the interpretation of the value of the AUC0-24/MIC for SMX in our MDR-
TB-patients at this time is difficult. The dose of SXT given to the MDR-TB patients was 
low compared to commonly used dosages for other infectious diseases. However, one 
has to keep in mind that the more conventional dosages of SXT are for the treatment of 
fast replicating bacteria and is often given as mono therapy. In our case the aim is slow 
growing M. tuberculosis in combination with other antimicrobial agents. For future study 
of SXT for MDR-TB it’s can be advised to also explore higher dosages to achieve higher 
drug exposure but tolerability may be a problem during prolonged treatment. 
The TB patients with HIV infections can have drug–drug interaction (DDI) when rifampin 
(RIF) is co-administered with SXT as mentioned in previous study [8] but this is of no 
concern in MDR-TB. Indeed, RIF decreases the concentrations of TMP and SMX significantly 
in serum but again, SXT would not be prescribed in individuals that can be treated with 
RIF and non-received RIF before starting the treatment with SXT.
Although our sample size was low, this retrospective study confirmed the safety of SXT in 
accordance with earlier studies that showed that SXT was safe and well tolerated when 
it was used as prophylaxis in adults with HIV infection who have pulmonary TB [28, 29]. 
SXT was well tolerated in MDR-TB patients and was not discontinued in any of 8 patients 
till the end of treatment and in 2 patients that are still on treatment. Only one patient has 
gastrointestinal complaints as a possible side effect of SXT following administration of 
960 mg of SXT daily. Therefore, the dose was lowered to 480 mg till the end of treatment. 
In our patients, the maximum Naranjo score of 5 was reached, in other words there is a 
probable relationship between the observed side effects and SXT. However hematological 
side effects including anemia, leucocytopenia and thrombocytopenia during treatment 
could be due to other antituberculosis drugs like linezolid [30, 31].  
The main limitation of this study is that there is a lack of data on the target (AUC/MIC 
value) to be reached to predict the efficacy of SXT in the treatment of TB. In the future, a 
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prospective study is needed to evaluate the PK and PD parameters of SXT in TB-patients. 
To determine ƒAUC0-24/MIC ratio of SMX for effective treatment along with suppression 
of the emergence of drug resistance, an in vitro infection model could be the suitable 
strategy as reported previously for moxifloxacin [32].
Comparing SXT with other drugs not registered for TB treatment but used in MDR-TB 
regimen, it has the great advantage that it is cheap and readily available all over the world.
 These are the first results on the inclusion of SXT in MDR-TB treatment in which drug 
susceptibility testing and SXT concentration measurements were combined. Based on our 
preliminary data we showed that SXT has a favorable PK profile in TB patients. 
Further in vitro PK and PD studies like a hollow fiber infection model or mouse model 
is warranted to establish target AUC/MIC value to predict the efficacy of SXT and 
consequently to set the optimal dose in the treatment of MDR-TB treatment. Preferably, 
PK/PD parameters of SXT, MIC of SXT should be measured alone and in the presence 
of other antituberculous drugs to detect the possible synergism between these drugs. 
According to the clinical outcome that showed no treatment discontinuation or serious 
side effects, the consistent PK values and relative low MIC values, this study could be the 
starting point for further exploration of SXT for MDR-TB treatment.
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Tuberculosis (TB) is one of the major infectious diseases in the world. TB treatment has 
become increasingly complicated because of co-infection with HIV and the emergence 
of resistant M. tuberculosis strains [1]. This stresses an urgent need for alternative, effective 
drugs with a minimum of toxicity. An old, inexpensive and well-tolerated drug like co-
trimoxazole (SXT) could be an attractive option for the treatment of MDR and XDR-TB [2]. 
SXT has been widely prescribed as prophylaxis for Pneumocystis jirovecii pneumonia (PCP) 
in human immunodeficiency virus (HIV)-infected persons, and has been associated with 
a significantly decreased risk for other opportunistic infections. Limited data are available 
on the in vitro SXT susceptibility of M. tuberculosis, but it appears that only SMX is effective 
against M. tuberculosis while TMP is not [2, 3]. 
The objective of this study was to evaluate the susceptibility of M. tuberculosis strains from 
normal sensitive TB and HIV-TB patients to SMX, and to compare these results with MICs 
values of SMX from MDR-TB patients that received SXT as part of their MDR-TB treatment 
in our previous retrospective study [4].
A total of 50 M. tuberculosis isolates were selected, 15 of which were normal sensitive TB; 
18 were from HIV/TB patients, of which 13 received SXT and five did not receive SXT as 
PCP prophylaxis during their treatment; and 17 from MDR-TB HIV-negative patients from 
the strain collection of the Tuberculosis Reference Laboratory at the National Institute for 
Public Health and the Environment (RIVM) in Bilthoven, the Netherlands.
The susceptibility of the respective M. tuberculosis strains to SXT was determined according 
to the Absolute Concentration Method. M. tuberculosis susceptibilities to SXT from HIV-TB 
patients were measured at baseline, prior to the start of TB treatment. For this study, M. 
tuberculosis was defined as susceptible to SXT when the MIC breakpoint is ≤ (1-2) mg/L, 
and resistant to SXT when the MIC breakpoint is (> 2 - ≥4) mg/L comparable to breakpoints 
of other bacteria.
MIC values were not normally distributed. The Mann–Whitney U-test was used to compare 
the MIC of MDR-TB, HIV-TB and drug-sensitive TB patients. Values are median ± interquartile 
range (IRQ). A P-value of <0.05 was considered significant.
MICs of SXT in clinical isolates of M. tuberculosis from patients with drug-susceptible TB, 
with or without HIV co-infection, and patients with MDR-TB were determined (Table1). 
The MIC of SXT is expressed as MIC of TMP, and the MIC ratio of TMP to SMX is 1:19.
Resistance of M. tuberculosis isolates from HIV-TB patients was only seen in one of the 13 
patients that received SXT as prophylaxis. Of the 13 HIV-TB patients that received SXT, 
only one did before TB treatment for five months. In the remaining 12 HIV-TB patients 
SXT was started with other anti-TB drugs for a median treatment period of 23 days 
(Interquartile range 9-105). No significant difference was observed between the MICs of 
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the isolates from drug-susceptible TB patients with either HIV/TB confection (P=0.927) 
or MDR-TB (P=0.168). Thirteen of 17 MDR-TB isolates tested were susceptible to SXT, and 
the remaining four MDR-TB isolates were SXT-resistant. Although this study showed that 
resistance of M. tuberculosis to SXT is limited in HIV-TB and MDR-TB patients, the number 
of strains was probably insufficient to detect the emergence of resistance. 
We speculated that SXT given to HIV-TB patients in combination with first-line treatment 
could have beneficial effects on the outcome of TB treatment, considering the susceptibility 
of M. tuberculosis isolates from HIV-TB patients and a synergistic effect of SMX and 
rifampicin plus an additional effect with ethambutol [5].  
The MICs of SMX reported in these isolates are remarkably similar to the MICs reported in 
a previous study [3]. In a small cohort study, SXT showed favourable drug exposure, a low 
MIC in the M. tuberculosis isolates tested, and only limited toxicity [4]. This suggests that 
SXT could be of value in the treatment of MDR-TB in the future.
Given that only a single patient received SXT prophylaxis before TB was diagnosed, our 
study was not designed to detect emergence of SXT resistance during treatment, which 
has been observed previously during long-term prophylaxis with SXT [6]. The other 
patients started prophylaxis with SXT at the time of TB diagnosis and HIV co-infection. 
In other clinical settings HIV may be diagnosed earlier than TB. Patients may receive SXT 
as a single drug long before TB is diagnosed and SXT resistance may be induced. For this 
reason, the emergence of resistance to SXT should be closely monitored and evaluated in 
areas of the world where the TB and HIV epidemics overlap.
In conclusion: because of the SXT susceptibility of M. tuberculosis isolates from HIV-TB and 
MDR-TB patients, SXT was found promising for further exploration in the treatment of HIV-
TB and MDR-TB patients. 
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1 0.5 <0.25 >2
2 1 b 0.5 <0.25
3 0.5 0.5 0.5
4 1 0.5 0.5
5 <0.25 4 0.5
6 1 0.5 0.5
7 0.25 0.5 >2
8 <0.25 0.5 >4
9 <0.25 1 2
10 0.5 <0.25 <0.25
11 0.5 0.5 0.5
12 0.5 <0.25 4
13 0.5 0.5 <0.25
14 0.5 0.5 <0.25




Median(IRQ) MIC 0.5 (0.25-5) 0.5 (0.5-0.5) 0.5 (0.25-2)
MIC< 2mg/l(n) 15 17 13
MIC > 2mg/l (n) - 1 4
TB, tuberculosis; HIV, human immunodeficiency virus; MDR, multidrug-resistant; IQR, interquartile range. 
a The MIC of SXT is expressed as the MIC of trimethoprim (TMP), and the MIC ratio of TMP to SMX is 1:19.
 b MIC of only one HIV/TB-positive patient who received SXT before TB treatment for 5 months 
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Co-trimoxazole is frequently used in the prophylaxis and treatment of pneumocystis 
carinii pneumonia. High plasma concentrations of sulfamethoxazole or trimethoprim are 
correlated with toxicity. There is, however, a large variation in pharmacokinetics observed 
which can lead to underexposure or toxicity. 
Results
We developed a novel liquid chromatography tandem mass spectroscopy (LC/MS-MS) 
method to analyse the components of co-trimoxazole, trimethoprim and sulfamethoxazole 
and its metabolite Sulfamethoxazole-N-acetyl. This new method is expeditious due to its 
limited sample pre-processing and a relatively short run-time of only 3 minutes.
Conclusion
This new method met the FDA requirements on linearity, selectivity, precision, accuracy, 
matrix effects, recovery and stability and is suitable for routine analysis and future 
prospective studies.
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Co-trimoxazole is a cheap and effective drug for the treatment and prophylaxis of 
pneumocystis carinii pneumonia (PCP) in HIV patients [1-3]. Improved survival was 
observed after initiation of combination antiretroviral therapy (cART) accompanied by 
co-trimoxazole treatment in HIV-infected patients [4]. According to the World Health 
Organization (WHO), co-trimoxazole should be continued until full recovery of the 
immune system [5]. 
A recent prospective cohort study in Switzerland showed that co-trimoxazole prophylaxis 
against PCP in the treatment of HIV reduced the incidence of tuberculosis [6]. Based 
on observations like this one and the in vitro activity of sulfamethoxazole against 
Mycobacterium tuberculosis [7-9] it has been suggested that sulfamethoxazole may 
be useful in the treatment of tuberculosis. In TB-HIV co-infected patients it was shown 
that trimethoprim and sulfamethoxazole drug exposure were highly variable between 
individuals [10, 11]. 
Well-known adverse events like neutropenia and thrombopenia were associated with 
increased serum concentrations of co-trimoxazole [10-12]. Furthermore, sulfamethoxazole 
is metabolized into Sulfamethoxazole-N-acetyl by N-acetyltransferase. This metabolite 
is less soluble than sulfamethoxazole, and is known to cause crystalluria resulting in 
obstruction and renal damage [13].  Blood concentration measurements of sulfamethoxazole, 
Sulfamethoxazole-N-acetyl and trimethoprim and subsequent dose adjustments could 
possibly reduce these side effects.
Although co-trimoxazole has been available for many years the PK/PD target of has not 
been elucidated yet. The effect of sulfamethoxazole seems to depend on the area under the 
curve (AUC) divided by the MIC, and the time above MIC (T>MIC) [14]. Sulfamethoxazole 
was effective in the treatment of melioidosis, which is caused by Bukholderia pseudomallei, 
with a T>MIC of 60% [14]. However, the validity of this PK/PD target in the treatment in 
other infectious diseases, such as PCP and possibly tuberculosis, is unclear. 
To be able to further explore the relation between co-trimoxazole drug concentration and 
efficacy and toxicity a suitable analytical method is required. Therefore, the objective of 
this study was to develop a simple, reliable and robust LC-MS/MS method to measure 
concentrations of trimethoprim, sulfamethoxazole and sulfamethoxazole-N-acetyl in 
human serum and plasma.
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Sulfamethoxazole, trimethoprim and trimethoprim-D9 were obtained from Sigma Aldrich 
(MO, USA). Sulfamethoxazole-N-acetyl and its internal standard sulfamethoxazole-
N-acetyl-D4 were purchased from Santa Cruz (TX, USA). Sulfamethoxazole-D4 was 
obtained from Alsachim (Illkirch Graffenstaden, France). The chemical structures of 
sulfamethoxazole, sulfamethoxazole-D4, Sulfamethoxazole-N-acetyl, Sulfamethoxazole-
N-acetyl-D4, trimethoprim and trimethoprim-D9 are shown in figure 1. Ammonium 
acetate and acetic acid were retrieved from Merck (NJ, USA). Trifluoroacetic acid and 
acetonitrile LC-MS were both obtained from Biosolve (Dieuze, France). Water was in house 
purified using a Milli-Q system (Millipore Corporation, MA, USA). 
Sulfamethoxazole-D4 was used as internal standard to quantify sulfamethoxazole. 
Sulfamethoxazole-N-acetyl was quantified using Sulfamethoxazole-N-acetyl-D4 and 
trimethoprim-D9 was used as internal standard for the trimethoprim quantification. 
The internal standard solution contained 200 ng/mL sulfamethoxazole-D4, 2,000 ng/mL 
Sulfamethoxazole-N-acetyl-D4 and 10 ng/mL trimethoprim-D9 dissolved in methanol 
(Merck, NJ, USA).
Buffer solution used in the gradient elution consisted of ammonium acetate (5.0 g/L), 
acetic acid (100%, 35 mL/L) and trifluoroacetic acid (100%, 2 mL/L).
FIGURE 1 -Structures of sulfamethoxazole, Sulfamethoxazole-N-acetyl and trimethoprim and their respectively internal standards sulfamethoxaz-
ole-D4, Sulfamethoxazole-N-acetyl-D4 and trimethoprim-D9.
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A TSQ Quantum Access Max (TSQ Quantum, Thermo Scientific, San Jose, CA, USA), 
supplied with a Finnigan Surveyor MS Pump Plus and a Finnigan Surveyor Autosampler 
Plus was used to perform the analysis. The mass spectrometer was equipped with a 
Thermo Scientific Hypurity Aquastar C18 (50*2.1 mm) column with a particle size of 5 µm. 
The spray voltage was set to 3500V. Sheath and auxiliary gas pressure were set on 35 and 
10 bar, respectively. Capillary temperature was set on 350 °C. Autosampler temperature 
was set to 10 °C.
The following ion transitions were selected: 254.0 → 156.1 (sulfamethoxazole), 258.1 → 
160.1 (sulfamethoxazole-D4), 296.1 → 198.0 (Sulfamethoxazole-N-acetyl), 300.1 → 202.1 
(Sulfamethoxazole-N-acetyl-D4), 291.1 → 230.0 (trimethoprim, figure 2a), 300.2 → 234.1 
(trimethoprim-D9, figure 2b).
Gradient elution was used as displayed in table 1. A continuous flow of 500 µl/min was 
used. Observed retention times were 1.75, 2.06 and 1.52 min for sulfamethoxazole, 
Sulfamethoxazole-N-acetyl and trimethoprim, respectively. The internal standards 
sulfamethoxazole-D4, Sulfamethoxazole-N-acetyl-D4 and trimethoprim-D9 eluted at 
1.73, 2.05 and 1.49 minutes after injection, respectively.
TABLE 1 - Gradient elution
Time (min) A (%) B (%) C (%)
0.00 5 90 5
0.40 5 90 5
0.40 5 77.5 17.5
2.00 5 70 25
2.01 5 0 95
2.60 5 0 95
2.61 5 90 5
3.00 5 90 5
A: ammonium acetate 5.0 g/L, acetic acid 100% 35 ml/L, trifluoroacetic acid 2 mL/L. B: ultra pure water, C: 
acetonitrile LC-MS
Alsaad.indd   69 12-10-2016   11:53:46
Chapter 4 Quantification of Co-trimoxazole in serum and plasma using tandem mass spectrometry
70 
FIGURE 2A - Trimethoprim product ion scan
FIGURE 2B - Trimethoprim-d9 product ion scan
Sample preparation
From the serum or plasma sample, 10 µL was transferred into an Eppendorf tube. After 
the addition of 250 µL of the internal standard solution, the sample was vortexed for 1 
minute. The vortexed sample was centrifuged for 5 minutes at 10,000 rpm and 200 µL of 
the extract with 500 µL ultrapure water was transferred into the vial. The vial was vortexed 
for 1 minute and was subsequently ready for analysis.
Analytical method validation
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guidelines [15] in human serum. Tests for selectivity, accuracy and precision, stability, 
recovery and matrix effects were carried out using LOW, MED and HIGH quality control 
(QC) samples. The concentration of the QC samples is displayed in table 2.
Selectivity for all three analytes was determined by analysing six separate serum samples, 
each from a different serum pool. Ion suppression was tested using a post-column infusion 
test [16].
The calibration curve of trimethoprim consisted of 8 concentration levels: 200, 500, 1,000, 
1,500, 2,500, 5,000, 7,500 and 10,000 ng/ml. Calibration curves of both sulfamethoxazole 
and Sulfamethoxazole-N-Acetyl consisted also of 8 concentration curves: 2,000, 5,000, 
10,000, 15,000, 25,000, 50,000, 75,000 and 100,000 ng/ml. The regression formulas were 
calculated using One-Way ANOVA. Linearity was tested with a Lack-of-fit sum of squares 
F-test.
Human serum was spiked with all QC concentrations separately and analysed in five 
replicates on three consecutive days. The accuracy was determined by calculating the 
difference of all measurements versus the nominal value for each QC concentration level 
of all three days combined (n = 15 per QC level). The within-day and between-day precision 
was calculated using the coefficient of variation (%) for each QC concentration level.
Stability was evaluated by spiking blank serum with LOW and HIGH QC concentrations of 
all three analytes. Bench-top stability was assessed after 240 hours at room temperature. 
Post-extraction stability was determined after 120 hours in the auto sampler at 10 °C. 
Freeze-thaw stability was determined after 5 cycles of freezing (at -20 °C) and thawing 
(at room temperature). The stability was calculated by comparing the test samples with 
freshly prepared calibration standards.
Dilution integrity of sulfamethoxazole and Sulfamethoxazole-N-acetyl was determined 
by diluting a 200,000 ng/mL serum sample to 20,000 ng/mL in five replicates on three 
different days with blank serum. For trimethoprim, dilution integrity was tested by diluting 
a 20,000 ng/mL solution to 2,000 ng/mL with blank serum. 
Blank serum was spiked with three QC concentration levels (LOW, MED and HIGH). The 
peak area of the peaks was compared to spiked extraction fluid to determine the matrix 
effect [17]. The recovery was calculated by dividing the peak area of spiked serum by the 
peak area of spiked extracted blank serum, again at three concentration levels (LOW, MED 
and HIGH). 
Matrix comparison tests were performed to compare the effect of human serum and 
human plasma on the analytical outcome. The calibration lines, in serum and plasma, 
were considered comparable when the 95% confidence interval of the intercept and 
slope were non-significantly different.
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LLOQ LOW MED HIGH
Nominal concentration (ng/mL)
Sulfamethoxazole 2,000 10,000 40,000 80,000
Sulfamethoxazole-N-acetyl 2,000 10,000 40,000 80,000
Trimethoprim 200 1,000 4,000 8,000
Accuracy (bias (%)) 
Sulfamethoxazole -2.8 -4.4 0.5 0.2
Sulfamethoxazole-N-acetyl -5.5 -7.2 -1.9 -2.6
Trimethoprim -1.9 -3.9 1.2 3.8
Within-day precision (CV (%))
Sulfamethoxazole 5.0 2.5 3.9 3.0
Sulfamethoxazole-N-acetyl 12.9 9.1 5.6 4.6
Trimethoprim 4.3 2.3 3.4 2.7
Between-day precision (CV (%))
Sulfamethoxazole 0.0 1.4 0.0 0.0
Sulfamethoxazole-N-acetyl 0.0 1.0 4.3 3.3
Trimethoprim 3.4 2.3 2.6 3.1
Recovery (%)
Sulfamethoxazole n.d. 93.1 88.8 97.9
Sulfamethoxazole-N-acetyl n.d. 94.2 86.9 105
Trimethoprim n.d. 93.7 90.1 98.3
Matrix effect (%)
Sulfamethoxazole n.d. 106.4 100.7 103.6
Sulfamethoxazole-N-acetyl n.d. 111.5 102.4 96
Trimethoprim n.d. 107.6 102.3 103.6
Autosampler stability (120h bias %)
Sulfamethoxazole n.d. -6.2 n.d. 0.6
Sulfamethoxazole-N-acetyl n.d. -13.7 n.d. -2.9
Trimethoprim n.d. -7.4 n.d. 4.1
Bench top stability (240h) (bias %)
Sulfamethoxazole n.d. 0.3 n.d. 6.7
Sulfamethoxazole-N-acetyl n.d. -0.4 n.d. 6.8
Trimethoprim n.d. 3.8 n.d. 11.1
Freeze-thaw stability (after five freeze-thaw cycles) (bias %)
Sulfamethoxazole n.d. -4.7 n.d. 1.6
Sulfamethoxazole-N-acetyl n.d. -7.4 n.d. -4.3
Trimethoprim n.d. -1.6 n.d. 6.3
n.d.: not done
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The chromatogram of the LOW concentrations of sulfamethoxazole, Sulfamethoxazole-N-
acetyl and trimethoprim is shown in figure 3. No peaks were observed in the chromatogram 
on the retention times of all three compounds in extracted blank serum and plasma. No 
ion suppression was observed.
FIGURE 3 - Chromatogram of the LOW QC concentrations in extracted samples of sulfamethoxazole, Sulfamethoxazole-N-acetyl and 
trimethoprim. 
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The properties of the calibration curves are displayed in table 3. All lines showed a 
correlation and regression coefficient of 0.99 or higher. 
















0.0730 ± 0.00115 0.997 0.995
Trimethoprim -0.0149 ± 0.0130 1.51 ± 0.0254 0.997 0.994
The accuracy of sulfamethoxazole, Sulfamethoxazole-N-acetyl and trimethoprim varied 
from -4.4 – 0.5%, -7.2 – -1.9% and -3.9 – 3.8%, respectively. Within-day precision (CV (%)) 
ranged from 2.3 – 12.9% for all three analytes at all QC concentration levels. Between-day 
precision (CV (%)) was determined and varied from 0.0 – 4.3%.
The bench top stability was evaluated; the bias in concentration of all compounds was 
calculated at ≤ 11.1%. The bias found in the post-extraction stability test varied between 
-13.7 – 4.1%. Freeze-thaw stability tests showed a bias of -7.4 – 6.3%, as shown in table 2. 
For sulfamethoxazole and Sulfamethoxazole-N-acetyl, matrix effects biased the analytical 
outcome with 0.7 – 6.4% and -4.0 – 11.5% respectively. A difference of 2.3 – 7.6% was 
found for trimethoprim. Recoveries varied between 88.8 – 97.9% for sulfamethoxazole, 
86.9 – 105.0% for Sulfamethoxazole-N-acetyl and 90.1 – 98.3% for trimethoprim.  
No statistical difference in slope and Y-intercept of the calibration line in serum and 
plasma was found for all three analytes sulfamethoxazole, Sulfamethoxazole-N-acetyl and 
trimethoprim. The matrix comparison curves are displayed in figure 4.
FIGURE 4 -Matrix comparison of sulfamethoxazole, Sulfamethoxazole-N-acetyl and trimethoprim in human serum and plasma
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We developed a novel robust LC-MS/MS assay to determine sulfamethoxazole, Sulfameth-
oxazole-N-acetyl and trimethoprim simultaneously in plasma or serum. This method is 
validated based on the FDA guidelines on precision, bias, recovery, matrix effect, stabili-
ty and dilution integrity. This new method can be applied in pharmacokinetic studies of 
co-trimoxazole in a range of infectious diseases. 
The LC-MS/MS method described in this paper has several advantages. All three compounds 
are quantified based on their corresponding deuterated internal standard, which is 
structurally highly similar to the analyte. In order to reduce costs, the concentrations of 
the internal standards are kept relatively low which resulted in internal standard responses 
comparable to LLOQ or LOW QC responses for the corresponding analytes. However, the 
response of the internal standard was sufficient to reliable quantify all analytes. Also, the 
method is validated for a broad concentration range and requires only a small amount of 
blood, which makes it also suitable for quantification of trimethoprim, sulfamethoxazole 
and its metabolite in paediatric studies.
A major problem during the development of the method was the separation of 
sulfamethoxazole and Sulfamethoxazole-N-acetyl with the LC system within the short run 
time, probably due to the similar structure and polarity of both compounds. We resolved 
this issue by adding ultrapure water to the sample mixture, which improved the separation 
within three minutes’ run time. This separation was further enhanced by optimizing the 
gradient elution.
Papers describing the analysis of co-trimoxazole in serum with HPLC-UV are already 
available [10, 18, 19]. However, the use of LC-MS/MS has several advantages above HPLC-UV, 
such as a higher specificity, sensitivity and an easier sample preparation. Only three papers 
could be retrieved addressing the validation of the analysis of co-trimoxazole in serum 
using LC-MS/MS [20-22]. Unfortunately, all three papers did not include the validation 
of Sulfamethoxazole-N-acetyl, the toxic metabolite of sulfamethoxazole. Furthermore, 
one paper used solid phase extraction (SPE), which is time-consuming and results in 
additional costs of consumables and a longer turn-around time. Also, trimethoprim was 
validated to 5,000 ng/mL, which is insufficient for TDM in the treatment of PCP where 
higher serum concentrations are observed [12]. Additional sample dilution will be needed 
in these cases.   These limitations make this method not ideal for TDM. Our method is able 
to analyse Sulfamethoxazole-N-acetyl and uses a simplified sample work-up, minimizing 
the time needed for analysis. In addition, the quantification of trimethoprim is validated 
to 10,000 ng/mL, which should be sufficient to measure trimethoprim levels during PCP 
treatment. 
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This new method makes it possibly to quantify co-trimoxazole and its toxic metabolite 
in serum and plasma in a reliable, efficient and robust way. This method can be used 
to further study the pharmacokinetics and pharmacodynamics in a range of infectious 
diseases in order to optimize treatment.
CONCLUSION
The new developed method proved to provide a reliable and robust quantification of 
sulfamethoxazole, its toxic metabolite Sulfamethoxazole-N-acetyl and trimethoprim in 




Co-trimoxazole is used for many infectious diseases, such as Pneumocystis carinii 
pneumonia.
In the era of the emergence of drug resistance, old antibiotics are re-evaluated for their 
potential against new threats.
Sulfamethoxazole, one out of two components of co-trimoxazole, may also be effective 
against multidrug resistant tuberculosis.
The pharmacokinetics of sulfamethoxazole are highly variable between individuals, which 
urges the need for dose adaptation guided by the blood concentration.
Experimental
A novel and robust liquid chromatography tandem mass spectrometry method to quantify 
trimethoprim, sulfamethoxazole and its nephrotoxic metabolite sulfamethoxazole-N-
acetyl was developed.
This new method requires only limited sample pre-processing without solid phase 
extraction and is able to separate all three analytes in a short chromatography runtime 
of 3 minutes.
Results
This new method was validated based on the FDA guidelines on selectivity, accuracy, 
precision, recovery, matrix effect and stability.
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A matrix comparison in serum and plasma was performed to confirm that both matrices 
were suitable for quantification.
Discussion
With this new method, the blood concentrations of trimethoprim and sulfamethoxazole 
can be measured for daily practice and future prospective studies.
FUTURE PERSPECTIVE
Drug resistance of various microbes is emerging. The activity of old antibiotics, such as co-
trimoxazole, against various microbes should therefore be re-evaluated. Sulfamethoxazole, 
one out of two components of co-trimoxazole, may be effective against multidrug resistant 
tuberculosis. With our novel method of analysis, new prospective research could be done 
to find the most optimal pharmacokinetic/pharmacodynamics (PK/PD) parameter of 
sulfamethoxazole in the treatment of tuberculosis.
With this PK/PD data, new regimens incorporating co-trimoxazole can be designed in 
the treatment of multidrug and extensively drug resistant tuberculosis. This to ultimately 
reduce the treatment duration needed to treat multidrug resistant tuberculosis and to 
generate treatment possibilities in the case of extensively resistant tuberculosis.
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ABSTRACT
For treatment of multi drug resistant tuberculosis (MDR-TB) there is a scarcity of 
antituberculosis drugs. Co-trimoxazole is one of the available drug candidates, and 
already frequently co-prescribed in TB-HIV co-infected patients. However, only limited 
data are available on pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-
trimoxazole in TB patients. The objective of this study was to evaluate PK parameters and 
in vitro PD data of the effective part of co-trimoxazole; sulfamethoxazole. In a prospective 
PK study in patients with drug-susceptible TB (age >18), SXT was administered orally in 
a dose of 960 mg once daily. One-compartment population pharmacokinetic modelling 
was performed using Mw\Pharm 3.81 (Mediware, Groningen, The Netherlands). The 
ƒAUC/MIC ratio and the time period in which the free concentration exceeded the MIC 
(T>MIC) were calculated. Twelve patients received 960 mg co-trimoxazole on top of first 
line drugs. The pharmacokinetic parameters of the population model were as follows 
(geometric mean ± SD): metabolic clearance (CLm) 1.57 ± 3.71 L/h, volume of distribution 
(Vd)0.30 ± 0.05 L*kg-1 lean body mass, drug clearance – creatinine clearance ratio (fr) 0.02 
± 0.13, gamma distribution rate constant (Ktr_po) 2.18 ± 1.14, gamma distribution shape 
factor (n_po) 2.15 ± 0.39. Free fraction of sulfamethoxazole was 0.3, but ranged between 
0.2-0.4. The median value of the MICs was 9.5 mg/L (IQR, 4.75-9.5) and of ƒ AUC/MIC ratio 
was 14.3 (IQR, 13.0-17.5). The percentage of ƒ T>MIC ranged between 43 and 100 % of the 
dosing interval. The PK and PD data from this study are useful to explore a future dosing 
regimen of co-trimoxazole for MDR-TB treatment.
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Tuberculosis (TB) annually still accounts for millions of cases of active disease and a 
significant number of deaths worldwide. Among patients who were reported to have 
TB in 2013, there were 1.1 million new cases of TB among HIV-positive patients and 480 
000 cases of multidrug-resistant (MDR)-TB [1]. The prevalence of MDR-TB has reached 
epidemic levels and is increasing in Africa, Asia, and Eastern Europe [2], while the majority 
is not treated according to the WHO recommendations.
Standard MDR-TB treatment includes first line drugs, for which the causative strain 
appeared susceptible, plus an aminoglycoside and a fluoroquinolone, with additionally 
drugs from group 4 and 5 to complete the regimen [3]. Unfortunately, the use of second 
line drugs including injectables such as aminoglycosides [4] is inconvenient in high 
prevalence areas; requiring parenteral administration [5]. In addition, there are other 
disadvantages of second line drugs compared to the two first line drugs isoniazid and 
rifampin such as their costs and toxicity. 
Co-trimoxazole; an antimicrobial drug that has been on the market since the late 1960ties, 
is cheap and relatively safe, is not registered for treatment of TB, but it could be active 
against MDR-TB [6].  Co-trimoxazole, a combination of trimethoprim and sulfamethoxazole 
is widely used for the prophylaxis and treatment of a range of other infectious diseases 
[7].  Also, in TB patients co-infected with the human immunodeficiency virus (HIV), 41% 
reduction in mortality was reported among patients receiving 960 mg co-trimoxazole in 
a randomized controlled trial in South Africa[8].  Another study in Switzerland confirmed 
that co-trimoxazole decreased the risk for development of TB in HIV-TB co-infected 
patients that did not receive combined Anti-Retroviral therapy (cART) and to a lesser 
extent in cART treated patients [9]. The occurrence of side effects after receiving 960 mg 
was similar in a placebo- and co-trimoxazole group in HIV-TB patients [10,11].  
Recently, in vitro studies and observational clinical data showed promising antimicrobial 
activity of sulfamethoxazole against Mycobacterium tuberculosis strains, revealing a MIC 
range 4.75-≤38mg/L and inactivity of trimethoprim against this bacteria [12-16].
The renal excretion of unchanged sulfamethoxazole is limited to about 20%.  Sulfameth-
oxazole is also acetylated by N-acetyltransferase into sulfamethoxazole-N-acetyl, which 
increases its solubility. The renal excretion of sulfamethoxazole-N-acetyl is the major path-
way of sulfamethoxazole removal [17,18 ]. 
The pharmacodynamic properties of SXT are not completely clarified but scarce literature 
favors the ratio of the area under the free concentration time curve (ƒ AUC) from 0 to 24 
h to MIC, and the duration of time a free drug concentration remains above the minimum 
inhibitory concentration (T>MIC) as potentially predictive PK-PD indices for determining 
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the efficacy of sulfamethoxazole [11,21].
In a previous retrospective study evaluating 8 MDR-TB patients receiving sulfamethoxazole 
in a dose of 400-800 mg once daily, the pharmacokinetic parameters showed little 
variability [15].
Based on a target ratio of ƒAUC0-24/MIC of 25 derived from other bacterial infections [19 ], 
and the safety data from studies in HIV-TB patients [8,11,20], supplemented with earlier 
data on pharmacokinetics from MDR-TB patients [15 ] and MIC values [21 ], we postulated 
that a dose of 960 mg once daily may serve as a suitable starting point for dose selection 
for MDR-TB treatment. 
To explore if the PK/PD target was met, a prospective open label study, evaluating co-
trimoxazole 960 mg once daily in drug sensitive TB patients, was performed. 
PATIENTS AND METHODS
Study design
This study was a prospective, open-label single-arm study and was performed at the 
TB-unit of the University Medical Center Groningen, location Beatrixoord in Haren, The 
Netherlands.  It was estimated that a sample size of 12 patients was sufficient to explore 
PK/PD target attainment after administration of SXT 960mg once daily. The study was 
approved by the medical ethical committee (METc 2013/195) and registered at clinical 
trials.gov (NCT01832987). The patients in this study received co-trimoxazole on top of 
their standard TB treatment (rifampicin, isoniazide, pyrazinamide, ethambutol) in a dose 
960 mg orally for four to six days (in order to prevent blood sampling within the weekends) 
to reach steady state, since the half time is approximately 10 hours [22].
Patients
Subjects eligible for inclusion were culture confirmed TB patients aged 18 years and older. 
Patients were enrolled in this study after they provided written informed consent. The 
patients were excluded if they had shown hypersensitivity to sulfonamides or trimethoprim, 
were pregnant or providing breast -feeding, had preexisting renal dysfunction (serum 
creatinine clearance ≤15 ml/min) or gastrointestinal complaints like diarrhea and vomiting. 
Patients receiving angiotensin converting enzyme inhibitors, potassium–sparing diuretics, 
methotrexate, dofetilide, phenytoin, sulfonylureas (glibenclamide, gliclazide, glimepiride and 
tolbutamide) or procainamide hydrochloride were also excluded from study participation. 
TB patients, concomitantly receiving treatment with vitamin K antagonist (acenocoumarol) 
Alsaad.indd   84 12-10-2016   11:53:47
5A pharmacokinetic evaluation of sulfamethoxazole 800 mg once daily in the treatment of tuberculosis 
85 
Chapter 5
were also excluded from participation in this study.
Additionally, the patients that had experienced an adverse effect to co-trimoxazole or 
similar antimicrobial drugs, patients with HIV or AIDS, severe damage to liver parenchyma, 
characterized by elevation of alanine-amino-transferase (ALAT; normal value <  45  U/l) 
and/or aspartate-amino-transferase (ASAT; normal value <40 U/l) three times the normal 
values or hematological disorders mainly anemia (hemoglobin level < 5.5 mmol/L), 
thrombocytopenia (leukocyte count >6 × 109/L) and agranulocytosis (granulocyte count 
<210*9/L) were also excluded.
Study procedures
Evaluation of medical chart of TB patients including demographic characteristics, 
underlying disease, localization of TB was done at day one of the study (baseline). 
Co-trimoxazole 960 mg (Sandoz®; Salutas Pharma GmbH, Barleben, Germany) was 
given orally in a single daily dose after a light breakfast. Blood samples were collected 
before administration and at 1h, 2h, 3h, 4h, 5h, 6h, 8h and 24 hrs after co-trimoxazole 
administration after at least 4 days of treatment (I.e. at steady state) [22,23]. 
The concentrations of sulfamethoxazole in human plasma samples were analyzed by a 
validated liquid chromatography-tandem mass spectrometry (LS-MS/MS) as described in 
detail earlier [15]. Measurement of sodium, potassium and creatinine levels and platelet 
count of the participants were done at baseline.
Drug susceptibility testing (DST) was performed at the National Mycobacterial Reference 
Laboratory (National Institute for Public Health and the Environment [RIVM], Bilthoven 
the Netherlands) by the Middlebrook 7H10 agar dilution method [24]. As recommended 
by the European Committee on Antimicrobial Susceptibility Testing guidelines, the MIC of 
co-trimoxazole is expressed as trimethoprim: sulfamethoxazole in the ratio 1:19. 
The unbound concentration of sulfamethoxazole in plasma ultra-filtrate was measured in 
the sample at 3 time points (2h, 4h and 24 hours). Individual pharmacokinetic parameters 
were calculated using MW\Pharm 3.81 KinFit module with a one-compartment model 
with lag time and a fixed estimated bioavailability of 1.
Population pharmacokinetics and model validation
The pharmacokinetic parameters were calculated using one compartmental analysis 
(MW\Pharm 3.81; Mediware, Groningen, The Netherlands), utilizing an iterative two-stage 
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Bayesian approach [25]. Based on these calculated parameters; a one compartmental 
population model was developed based on 800 mg sulfamethoxazole. The creatinine 
clearance was estimated using the Cockcroft-Gold formula [26].  The volume of distribution 
was normalized to the lean body mass (LBM). This model was optimized to fit the curves 
and to minimize the calculated AIC value.                                  
A two-compartment model showed no significant improvement in fitting the sulfameth-
oxazole concentration over time curves. The clearance was calculated with CL = CLm (met-
abolic clearance (L/h)) * BSA (body surface area (m2)) /1.85 + fr (drug clearance – creatinine 
clearance ratio) * CLcr (creatinine clearance (L/h)).         
Other descriptors in the formulas, such as the body weight, lean body mass and free fat 
mass did not improve the model fit based on the calculated Akaike information criterion 
(AIC) value. Also, the use of an allometric component b (standardized on 0.75) did not 
improve the model fit. The model was build using transit absorption rate with initial 
gamma distribution rate constant (ktr_po) and the gamma distribution shape factor 
(n_po) values of 2 ± 0.5 [27,28].  The bioavailability (F) was fixed to 1. The parameters of 
population model were assumed to be log-normally distributed and the variability in the 
pharmacokinetic parameters was calculated using Bootstrap analysis (n = 1000). The assay 
error was assumed to be normally distributed and was estimated at 0.1 + 0.1*C. Co-variate 
analysis was performed by MW\Pharm, assessing the influence of the age, weight, height, 
BSA, lean body mass and CLcr with the CLm, fr, Vd and Ka.
This population pharmacokinetic model was cross-validated using the n-1 method, where 
a model with one omitted patient was repeatedly used to calculate the AUC0-24h of this one 
omitted patient [29 ].
Furthermore, the model was externally validated using the PK data of a cohort of MDR-TB 
patients (n=8) using SXT 480 – 960 mg once daily (sulfamethoxazole dose: 400 – 800 mg) 
[15] .
Unbound concentrations of sulfamethoxazole were measured and were divided by the 
total concentration to find the free fraction of sulfamethoxazole, which was assumed 
to be comparable regardless of the concentration. Consequently, the unbound AUC0-
24h was calculated by multiplying the total AUC0-24h by the average free fraction. In turn, 
free AUC0-24h/MIC ratio was also determined based on the individual observations of 
the AUC0-24h multiplied by the average free fraction measured in 3 different samples of 
that particular patient. The time period in which the free concentration exceeded the 
MIC (T>MIC) of sulfamethoxazole was calculated. The maximum plasma concentration 
(Cmax) and minimum plasma concentration (Cmin) were assessed directly from the plasma 
concentration data.
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The difference of the population pharmacokinetic data and the observed data were tested 
by calculating the Root Mean Square Error (RMSE) and by constructing a Bland-Altman 
plot. Furthermore, the n-1 model was also compared with the observed data using both 
techniques. Predictive value of this model for the earlier population was evaluated using 
the RMSE. Pharmacokinetic parameters were compared using Wilcoxon Signed Rank Tests 
using SPSS 20 (SPSS, Virginia, IL).
RESULTS
Patient characteristics
A total of 12 patients (10 males and 2 females) with a median age of 30 (Inter Quartile 
Range (IQR), 25-50) years were enrolled in this study. They had a median body mass 
index of 20.2 kg/m2 (IQR, 18.7-21.9 kg/m2). All patients received 960 mg of co-trimoxazole 
once daily, which was equal to a median dose of 13 (IQR 11.8- 14.2) mg/kg. Diagnosis of 
TB was confirmed by culture and/or molecular tests, ten patients were diagnosed with 
pulmonary TB and one patient was diagnosed with spinal (extra pulmonary) TB and one 
with both pulmonary and pleural and spinal (extra pulmonary) TB. Baseline characteristics 
of TB patients are shown in table 1.
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TABLE 1- Baseline characteristics of TB patients receiving SXT (n=12)
Parameter                                                                                  Value (median± IQR)
Age (yr)                               30 (25-50) yr
Gender (Male/female) 10/2
Body mass index (kg/m2)                                                                                     20.2 (18.7-22)
Ethnicity
Europe
Africa     
America ‘
middle east      





















Extra pulmonary TB (pleural and spinal TB)                                                                    
11*
1
Other anti-TB drugs  
Isoniazid, rifampicin, pyrazinamide, ethambutol, 
moxifloxacin
Sodium level (mmol/L)                                                                              140 (139-141.2)
Potassium level (mmol/L)                                                                                    4 (3.7-4.2)
Creatinine clearance (ml/min/1.73 m2)                                                                              103.2 (106.0 – 112.0)
Platelet  count (×10*9/L)                                                                           292 (235.5-394.7)
* One of 12 patients was diagnosed with both pulmonary- and extra pulmonary TB.
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The observed pharmacokinetic parameters, as calculated using a one-compartment model 
with lag-time and a fixed bioavailability of 1, are shown in table 2. A large interindividual 
deviation in the rate and onset of the absorption is observed, which explains the large 
absorption coefficient (Ka) variation. The elimination phase (kel), however, was consistent 
and showed only little variation (median 0.09, IQR; 0.08 – 0.14 h-1). The median distribution 
volume per lean body mass varied was calculated at 0.025 (IQR; 0.020 – 0.028) L/kg.
TABLE 2- Observed pharmacokinetic parameters of sulfamethoxazole (800 mg)
Parameter Median (interquartile range)
AUC(mg/L*h) *1 566.6 (360.8 – 658.1)
CL (L/h) 1.34 (1.19 – 2.04)
Vd (L) 14.53 (11.82 – 16.82)
Vd/BW (L/kg) 0.23 (0.19 – 0.30)
T1/2 (h) 7.88 (4.95-8.27)
Kel (h
-1) 0.09 (0.08 – 0.14)
Ka (h
-1) 1.34 (0.72 – 4.49)
Lag time (h) 0.46 (0.17 – 0.63)
F 1 (fixed)
CL: clearance, Vd: volume of distribution, Vd/BW: volume of distribution divided by the body weight, T1/2: half time, 
k: elimination constant, Ka: absorption constant, F: bioavailability, *
1 calculated using the trapezium rule
Pharmacokinetics, Model validation and pharmacodynamics
The pharmacokinetic parameters of this population model are displayed in table 3. 
TABLE 3- Pharmacokinetic parameters of the population model (95% confidence intervals obtained by bootstrap analysis)
Parameter Mean (95% CI) ± st. dev. (95% CI) Shrinkage
CLm (L/h/1.85m
2) 1.57 (1.01 – 2.04) 3.71 (0.26 – 3.46) -0.8
Vd (L*kg
-1 lean body mass) 0.30 (0.25 – 0.39) 0.05 (0.02 – 0.11) 0.20
fr 0.02 (0.00 – 0.10) 0.13 (0.00 – 0.33) 0.08
Ktr_po (h-1) 2.26 (1.21 – 6.36) 1.05 (0.28 – 2.57) -0.02
N_po 2.12 (1.00 – 5.84) 0.73 (0.17 – 3.44) 0.51
CLm: clearance, Vd: volume of distribution, fr: drug clearance - creatinine clearance ratio, Ktr_po: gamma 
distribution rate constant, N_po: gamma distribution shape factor.
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Curves fitted to the population pharmacokinetic model resulted in a median AUC0-24h 
of 458.35 mg/L*h (IQR 380.65 – 553.9 mg/L*h). The fitted curve with the 5% and 95% 
percentiles and the observations are displayed in figure 1.
The observed and model calculated sulfamethoxazole concentrations are displayed in 
figure 2a and a Bland Altman plot of the concentrations is shown in figure 2b.
FIGURE 1- Sulfamethoxazole concentrations predicted by the model (line) and observations (crosses)
FIGURE 2 (a)- Passing and Bablok regression of the observed and model calculated Sulfamethoxazole concentrations (dashed lines, 
95% confidence interval). (b) Bland-Altman plot of the measured concentrations versus the predicted concentration)/2 and measured 
concentration-predicted concentration
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The mean value of free fraction of sulfamethoxazole that is responsible for antimicrobial 
activity was 0.3 (range; 0.2-0.4).
Covariate analysis indicated that none of the tested parameters (CLm, fr, Vd, ktr_po and 
n_po) was significantly correlated with age, weight, height, gender, BSA, lean body mass 
and CLcr (P > 0.05). 
Thereafter, the model was cross-validated using the n-1 validation procedure. The RMSE 
in the AUC was calculated at 7.6 h*mg/L with a coefficient of variation (CV) of the RMSE of 
1.7%.  Pharmacokinetic parameters resulting from the model and the n-1 validation were 
statistically equal (P < 0.05), except for the fr (P = 0.038). However, the difference between 
the fr from all individuals fitted to the model and fr resulting from the n-1 validation was 
relatively small (median fr 0.00 v.s. 0.17). A Bland-Altman plot assessing the difference in 
AUC0-24h between the model and cross validation calculations is displayed in figure 3.   
FIGURE 3-Bland-Altman plot cross-validation population pharmacokinetic model. Each dot represents a patient, where the coordinates 
of each point (x,y) are as follows:[modeled AUC+(n-1AUC)/2 and modeled AUC - (n-1AUC).
An additional model validation, in order to validate the model structure, was carried 
out by using the curves of eight patients as published earlier [15]. The clearance and 
volume of distribution were calculated based on these eight curves and compared to 
the pharmacokinetic parameters in the model of the earlier retrospective study [15]. The 
calculated values and their corresponding reported values are shown in table 4. 
TABLE 4-Retrospective validation
Parameters Mean (± st. dev.)
Model Alsaad et al. (15) p*
CL (L/h) 1.18 ± 0.52 1.21 ± 0.43 0.674
Vd (L*kg
-1 lean body mass) 0.30 ± 0.07 0.25 ± 0.04 0.050
CL: clearance, Vd: volume of distribution, Ka: absorption constant, F: bioavailability.
* Wilcoxon Signed Rank Test (two-tailed)
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Drug susceptibility testing revealed that all of M. tuberculosis isolates from 11 patients 
were susceptible to sulfamethoxazole with median value of MICs of 9.5 (IQR, 4.75 - 
9.5) mg/L. The median values of AUC/MIC and ƒAUC0-24h/MIC ratios after receiving 
800 mg sulfamethoxazole were 51.2 h.mg/L (IQR, 35.7 - 66.6) and 14.3 h.mg/L (IQR, 
13.0-17.5 h.mg/L) respectively. Thus, none of the patients had ƒAUC0-24h/MIC ratio of 
sulfamethoxazole greater than 25. The percentage of free T>MIC ranged between 43%-
100% of the dosing interval. 
DISCUSSION
In our study, we investigated the PK-PD parameters of sulfamethoxazole in patients with 
drug-susceptible TB receiving SXT on top of first line drugs. This is relevant, as it can be 
considered to be one of the first steps in exploring SXT as a potential alternative drug in 
the treatment for MDR-TB [6,15].
The observed pharmacokinetic parameters are calculated using a one-compartment 
model with lag time and a fixed bioavailability of 1 [19,15].  The absorption constant Ka 
showed to be variable with a large deviation, which might indicate that the absorption 
could be influenced by food intake. For this reason, we added a Bayesian simulated lag 
time to the population pharmacokinetic model to reduce Ka variability. Nevertheless, there 
was a high variability in the observed pharmacokinetic absorption constant. Therefore, 
we can conclude that the time to the maximum blood concentration is not homogeneous 
in our population. 
The model was also validated by refitting new population model using the curves 
collected during a retrospective study. The difference in CL and Vd of both models was 
statistically not significant (P= or > 0.05, table 4). However, the Ka found in our report was 
higher than the retrospective study of Alsaad et al [15]. This can be explained by the fact 
that a one-compartment model without lag time was used, which may have caused the 
difference in the absorption constant. 
Our results show that the median values of the exposure (AUC0-24) in drug-susceptible 
TB patients are lower than earlier reported data obtained from eight MDR-TB patients 
[15]. The lower AUC0-24 might be explained by drug-drug interaction with rifampicin, as 
this drug reduced the AUC0-24 of sulfamethoxazole with 23% in an earlier study [30,31] 
when co-administered in HIV patients. Interestingly, this percentage is comparable to the 
difference (22.2 %) in AUC between drug susceptible TB patients in this study and MDR-TB 
patients from our retrospective study [15].  
Moreover, the free (non-bound) fraction of sulfamethoxazole is responsible for the 
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antimicrobial activity [32]. The unbound fraction of sulfamethoxazole in TB patients was 
comparable to that in healthy human subjects in an earlier study [32]. The similarity in free 
fraction between TB patients and healthy subjects can therefore not explain the difference 
in AUC between healthy subjects and our patients. 
In our study we measured the concentrations of the drug only in serum rather than in 
epithelial lining fluid. For pulmonary infections, the concentration of drug in epithelial 
lining fluid (ELF) and alveolar macrophage cells may represent the antibiotic activity in the 
infection site. Unfortunately, sampling by bronchoscopic broncho-alveolar lavage without 
a clinical indication to collect ELF was not feasible. Therefore, the free concentration 
of drug in serum is the most reliable for the time being, as it is correlated with patient 
outcome [33]. 
The MIC values of sulfamethoxazole against clinical isolates of M. tuberculosis were 
similar to the MICs in previous studies [12-16]. We have previously shown that the MIC of 
sulfamethoxazole is not significantly different in MDR-TB patients versus drug susceptible 
TB patients [16]. The MICs reported in this study are therefore representative for the 
sensitivity of multidrug resistant M. tuberculosis.
The percentage of ƒ T>MIC in our study is more than 43% of the dosing interval. This is 
comparable with other drugs with anti-TB activity, like pyrazinamide in TB patients [34].
Because of lack of data on the clinically validated values of ƒ AUC/MIC and percentage 
of free T>MIC in TB patients, these parameters in our patients could be used as a starting 
point to evaluate the efficacy of sulfamethoxazole.
This study has several limitations. The PK parameters of sulfamethoxazole were determined 
while sulfamethoxazole was administered in combination with rifampicin, which likely 
resulted in a 23% lower exposure[23,24].   Another limitation is that absolute bioavailability 
could not be calculated as the sulfamethoxazole exposure after oral administration was 
not compared with the administration of an intravenous dose.  Additionally, the study was 
not designed to assess efficacy/outcome of sulfamethoxazole and therefore the PK-PD 
target index could not be evaluated in this study.
One of the possibilities to get more knowledge about the PK-PD index including f AUC/
MIC and T>MIC in relation to efficacy is to test sulfamethoxazole in a hollow-fiber infection 
model. Based on that target, the dose selection for an explorative phase II study in MDR-TB 
patients can be performed.  
In summary, this is the first report evaluating the PK-PD parameters of sulfamethoxazole 
in drug-susceptible TB patients. The established PK, encouraging antimicrobial activity of 
sulfamethoxazole against Mycobacterium tuberculosis strains in vitro and safety profiles in 
humans make this drug a suitable therapeutic option for treatment of MDR-TB in the near future. 
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ABSTRACT
Co-trimoxazole, consisting of sulfamethoxazole and trimethoprim, is used for the 
prevention of infections with Pneumocystis jiroveci pneumonia (PCP) in HIV-infected 
patients. In addition, data from HIV-TB co infected patients suggest that co-trimoxazole 
may be of added value in the treatment of TB. 
Unfortunately, the blood concentrations of sulfamethoxazole are highly variable between 
individuals, and this variation may attribute to its toxicity. Dried blood spots (DBS) have 
shown to be a reliable alternative to venous blood sampling, notably due to simple 
collection strategy and superior sample stability.
We developed a liquid chromatography tandem mass spectrometry analysis of 
sulfamethoxazole and its toxic metabolite, sulfamethoxazole-N-acetyl to quantify both 
compounds in DBS cards. The method was validated according to FDA and EMA guidelines 
and clinically validated. 
The stability of the compounds on the dried blood spots was acceptable with a bias of 
maximal -7.5% and -7.0% after 14 days at 50 °C and 1 month at 37 °C, respectively. The 
median difference in the area under the curve calculated on DBS compared to plasma 
samples was -5.8% (IQR -6.25 - -0.13%). 
This newly developed method showed to be reliable and robust and was fully validated. 
The stability of both compounds was sufficient to transport DBS cards from developing 
countries to a sophisticated laboratory to perform TDM. This method can be used in 
daily patient care and in future prospective pharmacokinetic studies exploring the use of 
sulfamethoxazole for TB treatment.
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Tuberculosis (TB) is a life threatening disease killing approximately 1.5 million people every 
year [1, 2]. TB is an infectious disease caused by Mycobacterium tuberculosis. Multidrug 
resistant (MDR) M. tuberculosis is resistant to at least isoniazid and rifampicin, the two 
most powerful first line anti-tuberculosis drugs [3]. The spread of MDR-TB is increasing, 
with an estimated 310,000 new infections in 2011 [1]. Therefore, much effort is needed to 
find new treatment options.
A potential candidate for MDR-TB is co-trimoxazole; a classic drug used against many 
types of infections [4-7]. Co-trimoxazole consists of trimethoprim and sulfamethoxazole. 
Trimethoprim is not active against M. tuberculosis but sulfamethoxazole showed in vitro 
activity against both TB and MDR-TB [8, 9]. A recent prospective cohort study showed 
that co-trimoxazole prophylaxis against Pneumocystis jiroveci pneumonia (PCP) in the 
treatment of HIV reduced the incidence of TB [10]. These considerations make this drug 
a potential candidate for the treatment of TB [4]. Co-trimoxazole has been shown to be 
effective in the prophylaxis of PCP in HIV-infected patients with a CD4 count below 200 /
mm3 [11]. It is therefore implemented in HIV treatment guidelines as standard care until 
there is evidence of immune recovery [11]. Although a fixed dose has been recommended, 
serum concentrations vary considerably between individuals. In patients with chronic 
liver disease, increased serum concentrations of sulfamethoxazole were found, correlating 
with a larger likelihood of toxicity [12]. Furthermore, sulfamethoxazole is metabolized by 
N-acetyltransferase to Sulfamethoxazole-N-acetyl, which has the tendency to precipitate 
due to concentration in the kidneys. This has a detrimental effect on the renal function 
[13]. A general advice is to drink 2 litres of water per day to avoid this.
To ensure that therapy with sulfamethoxazole is effective, the exposure to the drug 
needs to be high enough [14]. This exposure can be quantified using the area under the 
pharmacokinetic (PK) curve for 24 hours (AUC0-24h). The plasma AUC0-24h is a surrogate 
marker for the concentration at the site of the infection and the exposure to the infecting 
micro-organisms. To have a surrogate marker for the efficacy, and toxicity, the AUC0-24h 
needs to be related to the minimal inhibitory concentration of the micro-organism (MIC, 
AUC0-24h/MIC) [7, 14]. 
Dried blood spot (DBS) monitoring is a simple procedure to collect blood from a patient 
[15].  A DBS can be made with a few blood drops on a sheet of absorbent paper. The 
concentration of the drug of interest is subsequently measured in the dried blood spot. 
This method enables measuring blood levels of patients in outpatient clinics and in remote 
areas. The DBS can be easily stored and sent to a laboratory because of high sample 
stability [16]. From our own experience, it takes only a week to send a DBS card through 
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local post services from the rural country Ghana to our laboratory in The Netherlands with 
a 100% delivery rate up to now (n = 6, unpublished data). With the combination of high 
sample stability and easy sampling, therapeutic drug monitoring is feasible in rural parts 
of the world with a high frequency of HIV and/or TB.
Another additional advantage is reduced discomfort for patients. Moreover, medical 
personnel can take DBS samples after limited additional training. DBS analysis of anti-
TB drugs is increasingly proposed to replace venous sampling for therapeutic drug 
monitoring (TDM) [17-21]. Several analytical DBS procedures for TB drugs have already 
been published [22-24]. 
Although DBS seems a simple procedure in the field, method validation is not and requires 
additional validation for the effect of the haematocrit value and blood spot volume [16]. 
A higher haematocrit value results in a higher blood viscosity and affects the flux and 
diffusion properties of the blood [15]. This may result in a positive analytical bias [15]. 
The objective of this study was to develop and validate a simple method to detect and 
quantify sulfamethoxazole and Sulfamethoxazole-N-acetyl simultaneously in dried blood 
spots suitable for TDM. The DBS procedure was also evaluated in a prospective study.
PATIENTS AND METHODS
Patients
TB patients between 18 and 64 years of age with culture confirmed drug-susceptible M. 
tuberculosis were eligible for this prospective clinical trial. Co-trimoxazole 960 mg daily 
was added for 4 to 6 consecutive days to the standard treatment of TB to obtain a steady 
state concentration situation. On the 5th (± 1) day, three dried blood spots were collected 
1h, 5h and 8h post-dosage at the same time point as regular venous serum samples were 
taken. The study was approved by the local ethical committee (METC 2013/195) and 
registered at Clinicaltrials.gov (NCT01832987). Patients that participated in the study gave 
written informed consent.
Materials
Sulfamethoxazole was purchased from Sigma Aldrich (MO, USA). Sulfamethoxazole-
N-acetyl was obtained from Santa Cruz (TX, USA). The deuterated internal standards 
sulfamethoxazole-D4 and sulfamethoxazole-N-acetyl-D4 were purchased from Alsachim 
(Illkirch Graffenstaden, France) and Santa Cruz (TX, USA), respectively.
Ultrapure water was produced with a Milli-Q system (Millipore Corporation, MA, USA). 
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Ammonium acetate and acetic acid were both obtained from Merck (NJ, USA), while 
trifluoroacetic acid and acetonitrile LC-MS were purchased from Biosolve (Dieuze, France). 
Methanol was retrieved from Merck (NJ, USA). Whatman DMPK type C cards (Whatman, 
Kent, UK) were used for spotting the blood [25].
LC-MS/MS 
The LC-MS/MS apparatus and conditions were identical to the serum and plasma analysis, 
as published earlier [26]. In short, liquid chromatography separation took place with a 
Scientific Hypurity Aquastar C18 (50*2.1 mm, 5µm particles) column in a system with 
a Finnigan Surveyor MS Pump Plus and Finnigan Surveyor Autosampler Plus. Gradient 
elution with three mobile phases was applied to reduce the run-time to three minutes 
with a flow rate of 500 µL/min [26]. 
A TSQ Quantum Access Max (TSQ Quantum, Thermo Scientific, San Jose, CA, USA) tandem 
quadrupole mass spectrometer was used for both the serum and DBS MS/MS analysis. The 
spray voltage was 3500V, sheath and auxiliary gas pressure was set to 35 and 10 bar and 
the capillary temperature was set to 350 °C. 
To perform the analysis, the most sensitive ion transitions were used: 254.0 → 
156.1 (sulfamethoxazole), 258.1 → 160.1 (sulfamethoxazole-D4), 296.1 → 198.0 
(Sulfamethoxazole-N-acetyl), 300.1 → 202.1 (Sulfamethoxazole-N-acetyl-D4).[26] 
Preparation of solutions and QCs
The internal standard solution was composed of 0.2 mg/L sulfamethoxazole-D4 and 2.0 
mg/L Sulfamethoxazole-N-acetyl-D4 in methanol/water (80/20). Quality control blood 
samples were prepared in blood consisted of LLOQ (2 mg/L), LOW (10 mg/L), MED (40 
mg/L) and HIGH (80 mg/L) samples of sulfamethoxazole and Sulfamethoxazole-N-acetyl. 
DBS QC samples were produced by pipetting 50 µL of the quality control blood samples 
on a DBS card and drying it for three hours.
Sample preparation
A venous dried blood spot (VDBS) was made by pipetting 50 µL of the venous plain blood 
on a DBS paper. To analyse both VDBS and DBS, a paper disc of 8 mm was punched out 
each blood spot on the DBS. The IS solution was added (250 µL) and the sample was 
vortexed. After vortexing, the sample was placed in an ultrasonic bath for 10 minutes. 
Afterwards, the sample was vortexed again for one minute and subsequently centrifuged 
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for 5 minutes at 10,000 rpm. Of the extract, 200 µL was transferred in another vial, 500 µL 
ultra-pure water was added and 10 µL was subsequently injected on the column.
Method validation
Each calibration line consisted of eight different concentrations, as shown in table 1. 
TABLE 1- Calibration lines






Sulfamethoxazole 0.392 (± 0.004) -0.009 (± 0.023) 0.999 0.997
Sulfamethoxazole-N-
acetyl
0.112 (± 0.002) 0.005 (± 0.008) 0.998 0.996
Each concentration was prepared and measured in triplicate.  Both sulfamethoxazole and 
sulfamethoxazole-N-acetyl were measured in the range of 2.0 – 100.0 mg/L. Calibration 
curves were corrected for the internal standard based on peak area. The slope, intercept 
and correlation and regression coefficient were calculated by ANOVA.
Validation was performed according to the FDA and EMA guidelines. Selectivity was 
determined by analysing six blank blood spots retrieved from volunteers on our lab. 
All samples were tested for peaks on the retention times of sulfamethoxazole and 
Sulfamethoxazole-N-acetyl. Ion suppression was tested using a constant infusion test. 
Accuracy (coefficient of variation (CV)) was investigated by the analysis of LLOQ (2.0 mg/L), 
LOW (10.0 mg/L), MED (40.0 mg/L) and HIGH (80.0 mg/L) concentrations of both analytes 
in fivefold on three consecutive days. Precision (bias (%)) was examined within-run and 
between-run with the data from the accuracy determination. Dilution integrity was 
also tested during these three consecutive days by spiking a DBS card with 200 mg/L in 
fivefold with sulfamethoxazole or sulfamethoxazole-N-acetyl. The extract was diluted 1:10 
and analysed. The within-day and between-day precision were calculated using ANOVA.
The matrix effect was determined by spiking extracts of blank DBS with LOW, MED 
and HIGH QC concentrations of sulfamethoxazole or sulfamethoxazole-N-acetyl and 
comparing them with the peak area of spiked extraction fluid. The recovery was calculated 
by dividing the peak area of LOW, MED and HIGH concentration spiked DBS by the peak 
area of spiked extract of a blank DBS. Process efficacy was determined by dividing the 
peak area of a DBS spiked with LOW, MED and HIGH QC concentration divided by the peak 
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area of spiked extraction fluid.
The stability assessment was performed by analysing spiked dried blood spots (LOW and 
HIGH QC concentrations) stored for 14 days at 20, 37 and 50 °C and one month at 20 and 
37 °C. The peak area of analysed dried blood spots was compared with the peak area of 
freshly prepared samples.
Influence of haematocrit and blood spot volume
The influence of the haematocrit (Hct) value on the accuracy and precision was additionally 
assessed. In tuberculosis patients, an Hct value of 35% was expected [27]. We tested 
therefore Hct values of 20, 25, 30, 35, 40, 45 and 50%. The influence of the volume of the 
blood spot was also assessed by varying the blood spot volumes from 30, 50, 70 to 90 μl.
Clinical validation
Venous blood, VDBS and DBS concentrations were compared with a Bland-Altman plot 
and Passing and Bablok regression. According to EMA guidelines, the difference between 
DBS and serum concentrations should be within 20% in 67% of the cases [28]. Plots 
were constructed with SigmaPlot version 12 (Systat Software Inc., San Jose, CA, USA). 
Passing and Bablok regression was calculated using Medcalc version 15.8 (MedCalc 
Software bvba, Ostend, Belgium). The area under the curve (AUC0-24h) of sulfamethoxazole 
was calculated based on the measured DBS concentrations using a validated one-
compartment population pharmacokinetic model. The AUC0-24h based on the DBS samples 
was compared with the AUC0-24h calculated with full curves.
RESULTS
Method validation
No peaks were observed in six lots of blank samples at the retention times of the analytes 
(as shown in figure 1 (supplemental data)). No ion suppression was observed. The details 
of all three calibration lines are displayed in table 1. The correlation and regression 
coefficients were all >0.99.
Alsaad.indd   105 12-10-2016   11:53:49
Chapter 6 Dried Blood Spot analysis for Therapeutic Drug Monitoring of Co-trimoxazole in Patients with Tuberculosis
106 
SUPPLEMENTARY FIGURE 1- Chromatogram of sulfamethoxazole (LLOQ), sulfamethoxazole-D4, sulfamethoxazole-N-acetyl(LLOQ) 
and sulfamethoxazole-N-acetyl-D4.
The accuracy in measuring sulfamethoxazole and sulfamethoxazole-N-acetyl varied 
between -14.2 – 2.4% (as shown in table 2). The coefficient of variation between the 
measurements was 2.9 – 6.9% within-day and 0.0 – 9.5% between three days. The mean 
bias in determining the dilution integrity of sulfamethoxazole and sulfamethoxazole-N-
acetyl was 1% and -4% with an overall CV of 9.5% and 6.6%, respectively. Both accuracy 





Supplementary figure 1. Chromatogram of sulfamethoxazole (LLOQ), sulfamethoxazole-D4, 
sulfamethoxazole-N-acetyl (LLOQ) and sulfamethoxazole-N-acetyl-D4. 
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TABLE 2- Validation results
Criteria
Concentration level
LLOQ LOW MED HIGH
Nominal concentration (mg/L)
Sulfamethoxazole 2.0 10.0 40.0 80.0
Sulfamethoxazole-N-acetyl 2.0 10.0 40.0 80.0
Accuracy (bias (%))
Sulfamethoxazole -6.9 -2.4 0.9 2.4
Sulfamethoxazole-N-acetyl -14.2 -3.0 0.5 0.2
Within-day precision (CV (%))
Sulfamethoxazole 3.3 2.9 3.5 3.6
Sulfamethoxazole-N-acetyl 6.9 6.9 5.8 6.0
Between-day precision (CV (%))
Sulfamethoxazole 9.5 4.5 3.7 2.9
Sulfamethoxazole-N-acetyl 0.0 3.0 3.7 1.0
Matrix effect (bias (%))
Sulfamethoxazole n.d. 0.8 2.1 5.1
Sulfamethoxazole-N-acetyl n.d. 0.1 3.1 6.7
Recovery (bias (%))  
Sulfamethoxazole n.d. 86.4 96.1 87.5
Sulfamethoxazole-N-acetyl n.d. 93.2 103.7 89.6
Autosampler stability (7 days) (bias %)
Sulfamethoxazole n.d. -1.6 n.d. -2.8
Sulfamethoxazole-N-acetyl n.d. -3.0 n.d. -5.4
The results of the matrix effects and recovery evaluation are shown in table 1. The limits 
of the FDA and EMA were met at all three concentration levels. The recovery and matrix 
effects varied from 86.4 – 103.7% and 0.1 – 6.7%, respectively, and complied with the FDA 
and EMA defined limits.
The autosampler stability of sulfamethoxazole and sulfamethoxazole-N-acetyl was 
determined after 7 days. The bias was -1.6 – -5.4% compared to the nominal concentration.
The stability of the two analytes on the DBS is evaluated at various storage conditions 
during 14 days and one month as shown in figure 2. After 1 month at 37°C, the bias 
calculated for sulfamethoxazole and sulfamethoxazole-N-acetyl -7.0 – 3.9%. Storage at 
50°C for 14 days resulted in a deviation of -7.5 – -2.9% in comparison with the nominal 
concentration.
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FIGURE 2-Stability of Sulfamethoxazole (SMX) and Sulfamethoxazole -N-acetyl(A-SMX) at LOW and HIGH QC concentration exposed 
to various storage conditions.
Influence of haematocrit and blood spot volume
The influence of the haematocrit (hct) value is displayed in figure 1. At a hct value of 20%, 
bias varied from -15.3 – -8.8% for all analytes. A bias of 4.0 – 5.1% was found at a relatively 
high haematocrit value of 50%. The bias caused by varying the blood spot volume was 
-3.2 – 6.1%, as shown in figure 3.
FIGURE 3-Influence of the haematocrit and blood spot volume on the measured concentration. SMX: sulfamethoxazole, SMXA: 
sulfamethoxazole-N-acetyl.
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In total 12 patients were prospectively enrolled in this study. The median age was 31 (IQR: 
26 - 52) years with a median height of 175 cm (IQR; 168.2 – 180.0) and a median body 
weight of 61.5 kg (IQR; 56.4 – 67.2). All received 960 mg co-trimoxazole once daily.
Overall, 21 DBS samples of 9 patients were used to validate the method of analysis. 
The median haematocrit-corrected DBS concentrations were 20.8, 25.4 and 19.7 mg/L 
at 1, 5 and 8 hours’ post-dose. Median serum concentrations were 18.5, 35.0 and 30.8 
mg/L, respectively. The correlation between serum and haematocrit-corrected DBS 
concentrations was best described by: serum = -5.36 + 1.57 x DBS (Passing and Bablok 
regression). The 95% confidence interval of the intercept and slope was -11.43 – 0.40 and 
1.31 – 1.85, respectively. All haematocrit-corrected DBS, VDBS and serum sulfamethoxazole 
concentrations are displayed in figure 4a.
Figure 4a-Passing and Bablok correlation between sulfamethoxazole serum concentration and the haematocrit corrected DBS 
concentration (95% CI: dotted lines). Intercept: -5.36 (95% CI: -11.43 – 0.40), slope:1.57 (95% CI: 1.31 – 1.85) 
After correction using the proposed regression formula, three of all 21 DBS concentrations 
deviated more than 20% with the serum concentration (77.7%, 79.0% and 129.4%). In 
addition, we calculated the regression formula with only the samples 5 and 8 hours post-
dose. This relationship was best described by: serum = -2.88 (95% CI: -11.02 – 2.97) + 1.57 
(95% CI: 1.30 – 1.89) x DBS. None of the back calculated serum concentrations at 5 and 8 
hours’ post-dose differed more than 20% with the actual serum concentration using this 
regression formula.
For sulfamethoxazole-N-acetyl, the median haematocrit-corrected DBS concentrations 
were 3.3, 4.7 and 5.9 mg/L at 1, 5 and 8 hours post-dose. Median serum concentrations were 
quantified at 6.0, 10.0 and 9.9 mg/L. The correlation between the haematocrit-corrected 
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DBS concentration and serum concentration was best described by: serum concentration 
(mg/L) = 0.50 (95% CI -6.99 - 2.59) + 1.77 (95% CI 1.26 – 3.15) x DBS concentration (mg/L), 
(Passing and Bablok regression) as shown in figure 4b. The difference between the 
corrected DBS and the serum concentration was >20% in 6 of 17 cases (71.1% – 154.5%). 
FIGURE 4B- Correlation between sulfamethoxazole-N-acetyl serum concentration and the haematocrit corrected DBS concentration 
(95% CI: dotted lines). Intercept: 0.50 (95% CI -6.99 - 2.59), slope: 1.77 (95% CI 1.26 – 3.15) 
The median difference in AUC0-24h calculated on the DBS samples was -5.8% (IQR -6.25 - 
-0.13%) in comparison with full serum curves. A Bland Altman plot is displayed in figure 
4c. Two DBS-based AUC0-24h differed more than 20% (-23.7% - -22.8%). The coefficient of 
variation in the root mean squared error (CV(RMSE)) was 9.7%.
FIGURE 4C-Bland Altman plot of the AUC0-24h estimated based on full serum curves vs. based on DBS sampling.
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We developed a method to analyse sulfamethoxazole and sulfamethoxazole-N-acetyl in 
dried blood spots which was successfully validated based on the FDA and EMA guidelines 
on bioanalytical validation [28, 29]. Clinical evaluation showed that estimating the AUC0-
24h with DBS samples provides comparable results with traditional venous blood sampling, 
indicating that this method is suitable for daily patient care.
Both the haematocrit and blood spot volume influence the quantification of analytes on 
DBS cards [24]. The haematocrit value was obtained from all patients and was used to 
correct the analytical result. Bias caused by varying blood spot volumes was within 6% 
and was considered negligible.  
Due to compatibility with the serum and plasma analysis, we used identical mass 
transitions for all analytes of interest [26]. One problem which occurred during the 
development of the analytical method was the limited separation of sulfamethoxazole and 
sulfamethoxazole-N-acetyl. This problem was solved by adding 500 µL ultrapure water to 
the extract, increasing the hydrophilicity of the sample, which improved the separation. 
We used a gradient elution in order to further improve separation, and to minimize the 
total time of analysis to three minutes. In addition, we optimized the sample preparation 
turnover by comparing a 10 minute with a 60 minutes’ ultrasonic bath. No difference in 
response was observed.
One of the major advantages of this dried blood spot technique is the simplified 
logistics since no precautions concerning storage environment are required. The bias in 
concentration after 14 days at 50 °C or 1 month at 37 °C did not exceed 15%, indicating 
that extreme temperatures do not affect the analytical result. This indicates that this 
method is also suitable in countries with an extreme climate without cold chain transport 
requirements. With this method, TDM is within reach in developing countries when the 
DBS samples are transported to a sophisticated laboratory for analysis and TDM. 
The clinical validation of the analysis of sulfamethoxazole on DBS cards resulted in three 
deviations >20%, which meets the EMA requirements on cross-validation [28]. When 
using a regression formula based on the samples withdrawn 5 and 8 hours’ post-dose, 
no deviations >20% are observed in the calculated serum concentration based on the 
DBS concentration versus the true serum concentration. This indicates that the peripheral 
distribution of sulfamethoxazole is not complete one hour after ingestion of the drug. 
When all DBS results were entered in our pharmacokinetic model, two deviations of -23% 
and -24% in the AUC0-24h were observed compared to the AUC0-24h calculated on full serum 
curves. Furthermore, the RMSE was calculated at 9.7%, indicating that predicting the 
AUC0-24h of sulfamethoxazole with this DBS method is reliable and suitable for clinical use.
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The sulfamethoxazole-N-acetyl concentration determination is only to detect toxicity 
leading to renal toxicity. This analysis seems less accurate than the analysis of sulfameth-
oxazole itself. The difference between DBS concentration and serum concentrations 
might be caused by a large inter- and intraindividual variation in peripheral sulfameth-
oxazole-N-acetyl concentration. However, the concentration of the DBS cards was higher 
than the serum concentrations in cases where the deviation was >20%. Therefore, the 
sulfamethoxazole-N-acetyl concentration may be over-estimated using this methodology 
that may result in an overestimation of possible toxic concentrations. When an increase 
of sulfamethoxazole-N-acetyl is observed, additional clinical evaluation and reanalysis of 
sulfamethoxazole-N-acetyl in venous blood is needed to evaluate renal toxicity. Although 
serum creatinine is also feasible using dried blood spots [30], it is unfortunately no meas-
ure of renal toxicity as co-trimoxazole influences tubular excretion of creatinine [31]. 
Therefore, measurement of an additional marker, such as Cystatin C, is required to confirm 
renal toxicity [32]. Cystatin C could also be quantified using DBS [33].
The method that we developed and validated is suitable for analysis of sulfamethoxazole 
and sulfamethoxazole-N-acetyl and is validated according the FDA and EMA guidelines 
on sensitivity, selectivity, linearity, accuracy, precision and stability. One-point sampling 
combined with this DBS method provides a convenient and reliable method to assess the 
individual pharmacokinetics of sulfamethoxazole in the treatment of various infectious 
diseases, such as PCP. In addition, this method can be used in further prospective trials to 
assess sulfamethoxazole exposure. 
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Worldwide, the TB epidemic is in a crisis. TB control has largely failed to meet the 
Millennium Development Goals, and the newly drafted sustainable Development Goals 
for the next decades are unlikely to be met with current tools to fight TB [1, 2].
Current TB drug treatment regimens are challenged by increasing inhibitory concentrations 
for first– as well as second line TB drugs, with subsequently decreasing efficacy [3, 4]. 
Toxicity of most second-line drugs challenges doctors and patients to comply with 
treatment. Indeed, new TB treatment regimens are urgently needed. Only a few new TB 
products are in the pipeline and only two novel products have recently entered the market 
– bedaquiline and delamanid. For these new drugs, the long-term outcome has not been 
evaluated to date; early bactericidal activity is excellent but the largest challenge in TB 
treatment is to eradicate slowly replicating, metabolically inactive so-called ‘persister’ 
organisms. Rifampicin, in combination with pyrazinamide, provides the sterilizing 
capacity to allow for treatment duration of six months only, while fluoroquinolones e.g., 
moxifloxacin, have not been shown to further reduce treatment duration [5]. Discovery 
of new TB drugs is a difficult and expensive process and it takes a long time before new 
drugs reach the market. 
Apart from novel drugs that have already been developed for other infections and have 
been shown to have efficacy for TB in vitro and in vivo should therefore be considered 
for uptake in existing TB. Moreover, such drugs should urgently be evaluated for their 
potential role in fighting multidrug resistance tuberculosis (MDR-TB).
Co-trimoxazole (SXT) is one such old drug that is already available in the market and that 
has not been listed in WHO guidelines but it clearly has anti-TB activity. This drug could play 
an important role in the treatment of MDR-TB patients as an additive drug in a combination 
therapy [6]. To better understand the desired activity of this drug against MDR-TB, more 
knowledge about the safety, efficacy and accurate quantification of SXT in biological fluid 
is required. Therefore, re-inventing of SXT using modern methods and strategy is needed 
[7]. This drug has desired characteristics including good oral bioavailability following oral 
administration, penetration into cerebro-spinal fluid, low incidence of side effects, good 
tolerability, an encouraging susceptibility profile of M. tuberculosis, minimal interactions 
with other anti-TB and human infected virus (HIV) drugs, few interactions with CYP450 
enzymes; and low cost. Because of these characteristics, we were curious to evaluate the 
potential role of SXT in TB treatment.
Reviewing the literature on the pharmacokinetics (PK) and pharmacodynamics (PD) of SXT 
to determine the efficacy of SXT in the treatment of MDR-TB, we realized that only limited 
PK/PD data and information are available to date. Therefore, our aim was to evaluate these 
parameters in this thesis. 
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In our retrospective study the PK parameters of sulfamethoxazole (SMX), the effective 
part of SXT, were measured in MDR-TB patients. Plasma drug concentrations were lower 
compared to those measured in healthy volunteers and in patients infected with other 
diseases. This has been reported earlier for other drugs in TB patients who received anti-
tuberculosis drugs [8].  We believe this is due to reduced bioavailability, probably as a result 
of low intestinal absorption in these patients and is less in line with an increased volume 
of distribution or increased drug elimination. Reduced bioavailability and subsequent 
reduced plasma drug concentrations over time increase the possibility of drug resistance 
without necessarily reducing adverse drug reactions. Reduced effectiveness of anti-TB 
drugs may ultimately increase the chance of treatment failure [9-11]. Another important 
consideration is the PK variability among TB patients that drives the AUC0-24h/MIC ratio 
[12]. Indeed, this variability could be the main cause of the emergence of MDR-TB in the 
population, because this variation leads to low drug concentrations in several individuals; 
even if this results in effective treatment in most patients, it facilitates the emergence of 
drug resistance in others [13].
Fortunately, the population PK model of SMX from MDR-TB patients in our retrospective 
study showed a consistent PK profile and no significant variability in the area under the 
curve among these patients, the percentage of variation was 5.2% [14]. This contrasts 
with other drugs that have anti-TB activity like moxifloxacin, with a 9-fold inter-individual 
variability in AUC among MDR-TB patients [15]. 
Still there is a paucity of data about the susceptibility of M. tuberculosis strains from TB 
patients and a standardized guideline to measure the MIC of these bacteria against SMX 
is currently lacking as well; no break points have been determined. Also, the challenge 
of emergence of resistance to SMX when it is used in patients dually infected with HIV 
and TB who had received SXT for a long time as Pneumocystis jiroveci pneumonia (PCP) 
prophylaxis before TB was diagnosed has not been systematically studied. The results of 
SMX susceptibility testing of M. tuberculosis isolates between TB and TB-HIV and comparing 
with that of MDR-TB patient from the retrospective study were therefore promising, as no 
significant difference in MICs was observed among M. tuberculosis isolates in these patient 
groups.
SMX drug susceptibility of M. tuberculosis isolates from TB-HIV patients were tested. 
Although the result was beneficial, the risk of the development of active TB is a big 
challenge in these patients, and inadvertent mono-therapy with SMX for TB in patients 
in whom this diagnosis is missed presents a great risk to select drug-resistant mutants, 
thereby increasing the risk for the emergence of SMX-resistant clones of M. tuberculosis. 
Besides, adverse events are common among individuals on anti-TB therapy, as are drug-
drug interactions (DDIs) between antiretroviral and anti-TB drugs. For the effective 
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treatment of HIV-TB co-infection, pharmacokinetic DDIs should be avoided [16-18]. In 
comparison with new anti-TB drugs like Bedaquiline and DDIs with antiviral drugs like 
lopinavir and ritonavir [19], SMX has no clinically significant DDI when co-administered 
with indinavir sulfate [20, 21] and other antiviral drugs like didanosine [22] and zidovudine 
[23].  In low dosage as in PCP prophylaxis, SXT has mild and transient side effects in HIV-
TB co-infected patients. All these benefits of our drug over the above-mentioned anti-TB 
drugs contribute toward the expected role of SXT in the treatment of TB in TB-HIV co-
infected patients. 
For most TB drugs, and probably also for SMX, the most important factor to estimate the 
required dosage of SMX is through calculating the optimal PK/PD parameters of SMX. 
Therefore, we developed a liquid chromatography tandem mass spectrometry (LC-MS). 
This method to determine the concentration of SMX and its metabolites in plasma and 
serum has multiple advantages. And we therefore used this method in a prospective 
study for specifying the minimally required, or optimal AUC0-24/MIC ratio for SMX and 
testing our hypothesis that this ratio should exceed 25 to be effective in MDR-TB patients. 
In this study, we examined whether it is possible to achieve this target AUC0-24/MIC ratio 
of 25. None of the patients with drug susceptible TB who received 960mg of SXT once 
daily had ƒAUC0-24h/MIC ratio of SMX greater than 25. Therefore, we could not confirm our 
hypothesis that this ratio could exceed 25 after receiving 960 mg of SXT. However, the 
values AUC0-24/MIC ratio and f T>MIC will be precisely confirmed in the near future. The 
free fraction of SMX was measured for the first time in TB patients and was comparable to 
that in healthy subjects and therefore this fraction does not explain the difference in AUC 
observed between these two groups.
SXT has been associated with side effects related to its high concentration in serum and 
insoluble Sulfamethoxazole-N-acetyl and trimethoprim [24]. In the absence of current 
dose recommendations and the use of this product in patients with limited treatment 
options, therapeutic drug monitoring (TDM) would be the suitable solution to all patients 
with active TB, to identify those with low drug exposure and to reduce the side effects of 
SMX metabolites to increase the therapeutic benefit and decrease toxicity. There is indeed 
a close relationship between the PK of drugs especially, low AUC and the emergence of 
acquired resistance to anti-TB drugs among HIV-TB co-infected patients [25]. Therefore, 
TDM is especially important in HIV-infected patients who receive antiretroviral and anti-TB 
therapy [26,13].  
TDM has become easier to perform by using the Dried Blood Spot method that is to be 
preferred over classical blood sampling with its inherent difficulty in cold storage, and 
cold chain requirement until processing in a laboratory facility away from the point of 
care [27-30].       
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SXT was safe and well tolerated in MDR-TB patients compared to other drugs with anti-TB 
activity like linezolid. Though linezolid has been shown to be effective in the treatment of 
MDR-TB, serious side effects of linezolid and its cost could limit its use in the treatment, 
especially in low- and middle income countries that are typically highly endemic for TB 
and MDR-TB [31,32]. Based on the safety profile of SXT from our retrospective study in 
MDR-TB patients [14] and comparing it with safety of other drugs with anti-TB activity, 
SXT could be the safest alternative or adjunct anti-TB drug in TB treatment in the future. 
Another benefit of SMX is the mechanism of action of sulfonamides including SMX as 
inhibitor of carbonic anhydrase (CA) enzymes including (mtCA 1, mtCA 2 and/or mtCA 
3) which catalyzes the hydration of Carbon dioxide (CO2) and of dehydropteroate 
synthetase (DHPS) [33]. SMX is also inhibitor of dehydropteroate synthetase (DHPS), which 
catalyzes the addition of dihydropterindiphosphate to p-aminobenzoic acid (PABA). In 
experiments with overexpression of fol P1 and deletion of fol P2 genes in M. tuberculosis, 
these genes have been shown to play an important role in the anti-TB activity of SMX 
which is considered a clue for understanding the mechanism of action of SMX against M. 
tuberculosis [34]. 
In this thesis several aims were achieved. Limitations include the relatively small sample 
size, short duration of SXT administration to TB patients, gaps in our knowledge to 
assess the PK/PD target of SXT and lack of data about the role of SXT in the treatment 
of latent TB. Future clinical trials are urgently needed especially in low-and middle 
income countries where the TB burden is highest to confirm the bactericidal activity of 
SXT on actively replicating M. tuberculosis, to assess long-term safety and to explore the 
appropriate dose of SMX in MDR-TB patients. However, these trials for already existing 
drugs like SXT will be cheaper and easier to perform than those for the new anti-TB 
drugs, and clearly investigator-driven research could be designed to explore the possible 
role of SMX in MDR-TB. Development of novel drugs is a long process and few of these 
products reach the market. Furthermore, administration of SXT with other anti-TB drugs 
can affect the magnitude of AUC0-24/MIC ratio and consequently prevent the assessment 
of the individual efficacy of SXT in TB treatment. Therefore, an in vitro assay (a hollow fiber 
infection model, in vitro macrophage systems) and in vivo models (mouse or rat model or 
guinea pig model) should be designed to determine PK/PD correlations of SXT alone and 
in combination with other anti-TB drugs to identify the optimal dose of SXT and in turn 
to provide the maximal bactericidal activity against M. tuberculosis. Our data on PK in TB 
patients is very useful for this study as actual exposure in TB patients can be simulated 
in the hollow fiber model instead of drug exposure derived from healthy volunteers. The 
activity of SMX on the inhibition of M. tuberculosis intra- and extracellularly as reported in 
a previous in vitro study showed that SMX was more effective against MDR strains of M. 
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tuberculosis while it showed less inhibition also in high doses inside the macrophages [35]. 
We focused only on the PK parameters associated to PD parameters of SXT against 
metabolically active, fast replicating M. tuberculosis, although the activity against dormant 
bacilli and persisters would be desirable. Dormancy can be defined as a state of low 
metabolic activity when the mycobacteria fail to form colonies. Consequently, the first 
step in the treatment of TB is to kill dormant or slowly replicating tubercle bacilli that 
can persist and start replicating if and when conditions favor reactivation [36,33]. Further 
insight into the potential application of SXT against latent TB has to be established in an 
aerobic in vitro test system such as the Wayne model. 
SXT is widely used as prophylaxis in HIV patients who have a CD4 cell count <200 per mm3, 
and stopped when CD4 count is consistently above 200 cells per mm3 as a result of immune 
recovery in response to antiretroviral drugs [32]. Therefore, it is only ethical to evaluate the 
role of SXT in TB treatment in a prospective study in HIV-TB co-infected patients if CD4 
count >200 cells per mm3. Such study could evaluate the possible additional benefit of 
SXT group on top of HRZE. 
We have concentrated mainly on TB in adult patients while special attention must be given 
to children, especially with HIV-TB co-infection. Although the occurrence of TB in children 
constitutes a highly variable proportion of the total TB burden in the population - between 
<5%-20% [37], the optimal treatment of TB in children has not been widely studied, while 
children are in fact much more susceptible to develop TB after infection, due to their less 
matured immune system. Administration of SXT to infected children prolongs the survival 
of these patients and reduces the incidence of respiratory infections and hospitalization 
[38,39]. HIV-infected children benefit more from the antibacterial activity of SXT while 
receiving cART than adults [39, 40]. 
SMX has another benefit as prophylaxis; it is associated with reduced malaria incidence 
among infants with possible exposure to HIV infection. SMX’s protective benefits were 
more pronounced in asymptomatic infections, potentially affecting the malaria reservoir 
responsible for transmission. Therefore, SMX prophylaxis may have important individual 
and public health assets [41]. Although perhaps uncommon, MDR-TB may emerge among 
TB-infected children and alternative anti-TB drugs may therefore be needed [37]. More 
investigation on the clinical utility of SXT in the treatment of children infected with MDR-
TB is warranted. 
Last but not least, the data about the PK/PD target and the pharmacokinetic population 
model in this thesis are important tools to help explore the efficacy and the optimal dosage 
of SXT in the treatment of TB while minimizing the toxicity and the risk of resistance during 
treatment.The pharmacological properties and drug interactions of SXT are already well 
understood and with the work presented in this thesis, we have made important steps in 
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our knowledge about the pharmacokinetics, pharmacodynamics and short-term safety 
of SXT in TB patients. Anti-tubercular activity of SXT against active and latent TB in animal 
models and humans, and long-term safety in TB patients will be an interesting subject for 
further investigations.
In conclusion, further evaluations are needed to approve the use of SMX for the treatment 
of TB. If the efficacy of this drug is established, it will save the lives of many people that 
currently die every day because of TB in low- and middle-income countries.
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Treatment of multidrug-resistant tuberculosis (MDR-TB) is challenging because of the 
high toxicity of second-line drugs and the longer treatment duration compared to drug-
susceptible TB. In order to speed up the development of novel treatment for MDR-TB, we 
suggest considering expanding the indications of already available drugs in the market. 
In chapter 1 we systematically reviewed in vitro, in vivo and clinical anti-TB activity of six 
drugs with antimicrobial activity (phenothiazine, metronidazole, doxycycline, disulfiram, 
tigecycline and co-trimoxazole), which are not listed in WHO guidelines on MDR-TB 
treatment but could be potential candidates for evaluation against M. tuberculosis. Of the 
drugs effective against actively replicating TB, co-trimoxazole seems the most promising 
one because of its consistent pharmacokinetic profile, easy penetration into tissue, safety 
profile and encouraging in vitro activity against M. tuberculosis.
 Because of these characteristics, we were curious to evaluate the role of sulfamethoxazole, 
the effective component of co-trimoxazole in TB treatment. Limited data are available in the 
literature on the pharmacokinetics, pharmacodynamics and safety of sulfamethoxazole in 
the treatment of MDR-TB. Therefore, we evaluated PK and drug susceptibility along with 
the tolerability of sulfamethoxazole against Mycobacterium tuberculosis in a retrospective 
study (chapter 2). In this study the ratio of Area Under the free Concentration-time curve 
(ƒAUC) from 0 to 24 h relative to the minimal inhibitory concentration (AUC0-24h/MIC) was 
also evaluated as the best PK/PD parameter to predict the efficacy of sulfamethoxazole. A 
population pharmacokinetic model was developed showing a consistent PK profile and 
no significant variability in the area under the curve among the patients studied. The ratio 
of ƒ AUC0-24h/MIC of sulfamethoxazole exceeded 25 in only one patient. Co-trimoxazole 
was safe and well tolerated except for one patient who had gastrointestinal side effects 
after receiving 960 mg of co-trimoxazole. 
TB treatment has become increasingly complicated because of co-infection with human 
immunodeficiency virus (HIV). Therefore, in chapter 3 we measured in vitro susceptibility 
of M. tuberculosis to sulfamethoxazole in drug susceptible TB and co-infected HIV/TB 
patients and compared these results with MICs of sulfamethoxazole from MDR-TB patients 
in the retrospective study (chapter 2).  Because of the comparable susceptibility of M. 
tuberculosis isolates from HIV/TB and MDR-TB patients to sulfamethoxazole, we concluded 
that Co-trimoxazole is a drug that holds promise for further exploration in the treatment 
of HIV/TB and MDR-TB patients. 
Sulfamethoxazole exposure among HIV/TB co-infected patients appeared highly 
variable. We therefore decided to explore the relationship between sulfamethoxazole 
concentration, efficacy, and toxicity. First, we developed a LC–MS/MS analytical method for 
sulfamethoxazole. This method appeared to provide a reliable and robust quantification 
of sulfamethoxazole and its toxic metabolite Sulfamethoxazole-N-acetyl in serum and 
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plasma (Chapter 4). 
With this novel instrument for analysis (LC–MS/MS), we performed a prospective study 
in patients with drug-susceptible TB to optimize PK/PD parameters of sulfamethoxazole 
in the treatment of TB including AUC/MIC and T>MIC (chapter 5). None of these patients 
who received 960 mg of co-trimoxazole once daily in this study had ƒAUC0-24h/MIC ratio 
of sulfamethoxazole greater than 25. The percentage of f T>MIC ranged between 43 and 
100% of the dosing interval.  We consider these parameters as a starting point to explore 
the efficacy of sulfamethoxazole and clearly, additional studies are needed to find the 
precise PK/PD targets and consequently to set the optimal dose of co-trimoxazole for 
MDR-TB treatment. 
In chapter 6, we used dried blood spots (DBS) as an alternative collection procedure to 
venous blood sampling in order to determine the concentrations of sulfamethoxazole 
and its metabolites. The stability of these compounds was sufficient to transport DBS 
cards from highly endemic countries for TB notably, low- and middle income countries 
around the world to a sophisticated laboratory to perform therapeutic drug monitoring. 
The calculated AUC0-24h with DBS samples was comparable to that with venous blood 
sampling. As even extreme environmental temperatures do not affect the analytical results 
of sulfamethoxazole and its metabolites during sample collection and transportation, this 
method is suitable for clinical practice and especially in countries with an extreme climate. 
In this thesis we have described the PK and PD parameters of sulfamethoxazole in different 
groups of TB patients and also the desired characteristics of sulfamethoxazole in different 
groups of TB patients. In the future in vivo and clinical studies as described in chapter 7 are 
required to show the precise role of sulfamethoxazole in the treatment of TB. 
Alsaad.indd   131 12-10-2016   11:53:53
SAMENVATTING
Alsaad.indd   132 12-10-2016   11:53:54
SAMENVATTING
NEDERLANDSE
Alsaad.indd   133 12-10-2016   11:53:54
 Nederlandse samenvatting
134 
Behandeling van multidrug-resistente tuberculose (MDR-TB) is een uitdaging vanwege 
de hoge toxiciteit van tweedelijns geneesmiddelen en de langere duur van de 
behandeling vergeleken bij geneesmiddel-gevoelige TB. Om het ontwikkelen van nieuwe 
behandelingen voor MDR-TB te versnellen, stellen wij voor de indicaties van reeds op de 
markt beschikbare geneesmiddelen uit te breiden. In hoofdstuk 1 hebben we systematisch 
de in vitro (in de reageerbuis), in vivo (in diermodellen), en klinische anti-TB-activiteit van 
6 geneesmiddelen met antimicrobiële werking (fenothiazine, metronidazol, doxycycline, 
disulfiram, tigecycline, en co-trimoxazol) beoordeeld. Deze geneesmiddelen komen niet 
voor in de WHO richtlijn voor MDR-TB behandeling maar moeten worden beschouwd als 
mogelijke geneesmiddelen tegen M. tuberculosis. Van de geneesmiddelen die effectief 
zijn tegen actief-delende TB bacteriën, lijkt co-trimoxazol  de meest veelbelovende te 
zijn vanwege het voorspelbare geneesmiddelconcentratie, gemakkelijke doordringen in 
het weefsel, veiligheidsprofiel, en veelbelovende in vitro activiteit tegen de TB bacterie 
(Mycobacterium (M.) tuberculosis).
Vanwege deze eigenschappen wilden wij de rol evalueren van sulfamethoxazol , het actieve 
bestanddeel van co-trimoxazol in de behandeling van TB. Beperkte data is beschikbaar in de 
literatuur over de farmacokinetiek, farmacodynamiek , en veiligheid van sulfamethoxazol 
in de behandeling van MDR-TB. Daarom hebben we geneesmiddelconcentratie en 
minimaal remmende concentratie samen met de verdraagbaarheid van sulfamethoxazol 
tegen de TB bacterie geëvalueerd in een retrospectieve studie (hoofdstuk 2). In deze studie 
is de verhouding van het oppervlak onder de concentratie-tijd curve van de niet-eiwit 
gebonden of vrije fractie (fAUC) van 0 tot 24 uur ten opzichte van de minimaal remmende 
concentratie (AUC0-24h/MIC) geëvalueerd als de beste parameter om de werkzaamheid van 
sulfamethoxazol te voorspellen. Een populatie farmacokinetisch model werd ontwikkeld. 
De variabiliteit in de geneesmiddelconcentratie gedurende de gehele dag van de 
onderzochte patiënten was beperkt. In slechts 1 geval was de verhouding van fAUC0-24h/
MIC hoger dan 25. Co-trimoxazol was veilig en werd goed verdragen, behalve bij één 
patiënt die maag-darm bezwaren had na inname van 960 mg co-trimoxazol.
TB-behandeling is gecompliceerder geworden door co-infectie met humaan immunode-
ficiëntie virus (HIV). Daarom is in hoofdstuk 3 de in vitro gevoeligheid gemeten van M. tu-
berculosis voor sulfamethoxazol in geneesmiddel-gevoelige TB en co-geïnfecteerde HIV/
TB patiënten en zijn deze resultaten vergeleken met MIC’s van sulfamethoxazol van MDR-
TB patiënten uit de retrospectieve studie (hoofdstuk 2). Vanwege de vergelijkbare gevoe-
ligheid van M. tuberculosis isolaten van HIV/TB en MDR-TB patiënten voor sulfamethoxaz-
ol, hebben we geconcludeerd dat co-trimoxazole een geneesmiddel is dat veelbelovend 
is voor verder onderzoek in de behandeling van HIV/TB en MDR-TB patiënten.
De sulfamethoxazol bloed concentratie in HIV/TB co-geïnfecteerde patiënten bleek zeer 
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   variabel. Derhalve besloten we de relatie tussen sulfamethoxazol concentratie, effectiviteit 
en toxiciteit te verkennen. Daartoe ontwikkelden we eerst een gevoelige analysemethode 
voor sulfamethoxazol met behulp van vloeistof chromatografie en massaspectrometrie 
(LC-MS/MS). Deze methode bleek een betrouwbare en robuuste kwantificatie van 
sulfamethoxazol en het toxisch metaboliet n-acetyl-sulfamethoxazol in serum en plasma 
te verschaffen (hoofdstuk 4).
Met de LC-MS/MS deden we een prospectieve studie in patiënten met geneesmiddel-
gevoelige TB voor het vaststellen van de PK/PD parameters van sulfamethoxazol in de 
behandeling van TB, inclusief AUC/MIC en T>MIC (hoofdstuk 5). Geen van deze patiënten 
die 960 mg co-trimoxazol eenmaal per dag kregen in deze studie had een ƒAUC0-24h/MIC 
verhouding van sulfamethoxazol boven de 25. Het percentage van f T>MIC varieerde van 
43 tot 100% van het doseringsinterval. We beschouwen deze parameters als startpunt 
voor het verkennen van de effectiviteit van sulfamethoxazol en het is duidelijk dat 
er aanvullende onderzoeken nodig zijn om de precieze PK/PD doelen te vinden en 
vervolgens de optimale dosering van co-trimoxazol bij de behandeling van MDR-TB vast 
te stellen.
In hoofdstuk 6 hebben we op filterpapier gedroogde monsters van een enkele druppel 
bloed (DBS) gebruikt; DBS is een alternatief voor uit de ader (veneus) afgenomen 
bloedmonsters om de concentraties van sulfamethoxazol en haar afbraakproducten 
(metabolieten) te bepalen. De stabiliteit van deze verbindingen was voldoende om 
DBS kaarten te ge bruiken voor landen met lage- en middeninkomens waar TB nog veel 
voorkomt. Deze gedroogde bloedmonsters kunnen makkelijk verstuurd worden naar 
centrale laboratoria (vaak in de hoofdstad) of naar een internationaal referetie centrum om 
therapeutische drugmonitoring uit te voeren. De berekende AUC0-24h van DBS monsters 
was vergelijkbaar met dat van veneuze bloedmonsters. Omdat zelfs hogetemperaturen 
geen invloed hebben op de analyseresultaten van sulfamethoxazol en haar metabolieten 
tijdens monstername en transport, is deze methode geschikt voor de klinische praktijk en 
vooral in landen met een warm klimaat.
In dit proefschrift hebben wij de PK en PD parameters van sulfamethoxazol in verschillende 
groepen van TB patiënten beschreven, evenals de gewenste eigenschappen van 
sulfamethoxazol in de verschillende groepen van TB patiënten. In de toekomst zijn in vivo 
en klinische onderzoeken nodig zoals beschreven in hoofdstuk 7, voor het aantonen van 
de precieze rol van sulfamethoxazol in de behandeling van TB.
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